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Summary
In this study we have started from a real odontoiatric clinic problem, which affects 
a high percentage of patients: edentulism.
Implant  therapy,  started  by  Prof.  Branemark  in  the  seventies  thanks  to  the 
discovery of osseointegration, has developed  in the last 15 years.
This therapy represents a valid solution for edentulous patients, although it cannot 
always be used.
Severe osseous resorption or anatomical limitations hinder the use of implant and 
force the employ of biomaterials and/or autologous bone, which, according to the 
latest scientific research, represents the gold standard.
However, intraoral bone graft is not always well tolerated by patients and, in cases 
of severe atrophy, the quantity of bone that can be taken from the oral cavity is not 
enough for complete regeneration.
Although implant therapy represents the best solution for edentulous patients, in 
the latest years a biological complication has become more and more frequent: 
peri-implantitis.
It represents a serious problem since it begins with an inflammation of peri-implant 
hard  tissues  that  clinically  leads  to  a  loss  of  peri-implant  alveolar  bone  and, 
eventually, to the loss of the implant as a whole.
According to the most recent literature, this serious problem affects 10% of the 
patients and 4% of the implant sites after 10 years of follow-up. 
To make this pathology even more serious is the little knowledge that clinicians 
and researchers have about early diagnosis, etiopathogenesis and therapy.
The purpose of this study is to address both edentulism and consequent osseous 
regeneration, as well as the problem of peri-implantitis from a biological point of 
view and with the help of tissue engineering.
In particular, we wanted to test the ability of stem cells taken from adult tissue to 
favor - in shorter time - osseous regeneration and implant osseointegration both in 
vitro and on small and large animals.
Furthermore, we have tested the anti-inflammatory ability of stem cells in bone 
tissue. Finally, with regard to the problem of peri-implantitis, we have searched for 
predictive genetic factors in order to possibly identify patients at risk.
Preliminary results of studies performed both in vitro and on animal enable us to 
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state that:
 It is possible to isolate stem cells from different adult tissues (adipose 
tissue, dental pulp) and test their genetic stability.
 For the cells isolated from dental pulp, we could identify an important 
connection between patient’s age and ability to differentiate and proliferate.
 Stem  cells  combined  with  different  scaffolds  are  able  to  foster 
osseous regeneration faster.
 It  has been recognized an actual  anti-inflammatory ability  of  stem 
cells in bone tissue.
 Preliminary  results  on  the  use  of  CGH  as  genetic  predictive 
technique  for  peri-implantitis  are  encouraging  since  they  foreground  a 
correlation between the genetic alteration of some chromosomal tracts and 
clinical onset of the disease.
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Introduction
Edentulous patients
The absence of good oral health in adults can manifest into social, physical, and 
emotional health issues. Poor oral health, therefore, negatively impacts on quality 
of life. Oral health is instrumental to older people’s health, life satisfaction, quality 
of life and their perception of self. [Mitchell et al. 2013; Mariño et al. 2013]
In addition, clinical data demonstrates that poor oral health increases the risks to 
health in the same way as any disease of the body system  [health 2001]. The 
interconnections between poor oral health, in particular periodontal disease, and 
other acute and chronic medical conditions (e.g. pneumonia, cerebrovascular and 
cardiovascular disease as  acute myocardial infarction stroke and coronary heart 
disease  [Emingil  et  al.  2000;  Elter  et  al.  2003;  Hung  et  al.  2007] diabetes, 
nutritional  deficiencies  are  now  established  [Genco  and  Van  Dyke  2010; 
LOESCHE et al. 1998].
The ability to chew and swallow food comfortably, to speak and to interact socially, 
can  be  compromised  by  common  oral  diseases  and  partial  or  full  edentulism 
conditions. (Figure 1, Figure 2)
Partial edentulsim is the absence of at least one natural tooth, and full edentulism 
is the complete absence of all natural teeth. 
Thorstensson H. and Johansson B. [Thorstensson and Johansson 2010] suggests 
that  the  main  cause  of  tooth  loss  is  due  to  caries  in  about  55% of  swedish 
individuals of the study, up to the oldest age substantial increase in frequency to 
75%. Periodontitis, as a reason for tooth loss, is of minor importance compared 
with caries but increase steadily over the lifespan from 18 to 33%. Other reasons 
are toothache, endodontics and tooth/root fractures. 
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Figure 1: edentulous patient with severe atrophy: lateral view, frontal view
Figure 2: orthopantomography
Oral health status and quality of life are strictly related. 
The ability to chew  food may affect dietary choices and nutritional intake and have 
consequences for  general  health  [Joshipura  et  al.  1996a;  KRALL et  al.  1998]. 
Edentates have been shown to have a significantly lower fruit and vegetable intake 
than the fully dentate. Tsakos G et al.[Tsakos et al. 2010] suggests that edentate 
individuals consumed 50.7 g (27.0, 74.3) fewer fruits/vegetables per day than the 
dentate.  Joshipura  et  al.  [Joshipura  et  al.  1996b] investigated  the  association 
between tooth loss and diet. The edentulous had a higher intakes of total fat and 
saturated fat and a lower intake of non-starch polysaccharide (NSP) (dietary fiber), 
β-carotene,  and  fruits  and  vegetables  than  subjects  with  25  or  more  teeth. 
Consumption of fruit and vegetables is also positively related with the number of 
natural teeth. Patients with loss of functional dentition and denture-wearing result 
in  selective food intake,  hard foods  and foods cointaining seeds and pips  are 
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avoided (such as tomatoes,  grapes and whole grain bread)  with the effects of 
material deprivation on nutrient intake [Moynihan and Bradbury 2001].
Oral health is not only related to masticatory function and chew ability. Esthetic  
and psycological problems are often related with loss of teeth. Missing teeth can 
have negative consequences on self-image, social interaction and psychological 
health. Interviews done on edentulous patients by Fiske J et al. [Fiske et al. 1998] 
suggests the main themes identified in reaction to tooth loss were: lowered self-
confidence, altered self-image, dislike of appearance, an inability to discuss this 
taboo subject,  a  concern  about  prosthodontic  privacy,  behaving  in  a  way  that 
keeps the tooth loss secret,  altered behaviour  in socialising and forming close 
relationships, premature ageing, and lack of preparation. Active ageing requires 
maintenance of oral health status: desire for physical attractiveness and interest in 
appearance does not decline with age [Xiaoxian Meng et al. 2007]; consequently 
in  edentates  patients  complete  prosthetic  treatment  contributes  to  maintaining 
aesthetic  appearance,  fluent  speech  and  suitable  occlusal  arrangements  for 
masticatory efficiency [Quran et al. 2001].
Papadaki E. and Anastassiadou V.  [Papadaki and Anastassiadou 2012] correlate 
emotional  reactions  to  tooth  loss  with  denture  satisfaction  attributes  in  elderly 
complete denture wearers.  Questionnaire  for  Emotional  reactions to  tooth  loss 
showed that 60% of patients had not only difficulties in accepting their tooth loss, 
but 65% of the younger participants and 47% of the older ones required more than 
6 months to come to terms with it. The same pattern was revealed regarding time 
of acceptance. Four key feelings associated with losing the last tooth/teeth identify 
sensation of  relieved in 1/4 of the subjects, sadness in 1/4 and resignation and 
oldness in 1/5.  Older  subjects more often felt  relieved with tooth clearance, in 
contrast to the younger subjects who were more likely to develop negative feelings 
of bereavement. The study suggests that a substantial proportion of patients were 
satisfied with their complete dentures rehabilitation but some patients experienced 
increased social and psychological problems related to their edentulousness and 
the  wearing  of  complete  dentures.  The  aesthetic  and  functional  aspects  of 
complete dentures affected both patients’ social behaviour and self-confidence as 
going  out  and  laughing  in  public,  speaking  difficulties  correlated  with  avoiding 
social interaction. 
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The  edentoulus  patient  has  a  resorption  of  alvelar  bones.  This  condition  in 
association with the absence of  teeth create physiognomy changes as leak of 
intraoral  volume  and  deflation  of  perioral  tissues  (lips  and  cheeks).  Esthetics 
changes could create psychological problems and loss of self-esteem.
Carossa  S.  et  al  [Carossa  et  al.  2000] investigated  the  correlation  between 
edentulism,  sleep disorders and arterial  hypertension.  Respiratory disturbances 
during  sleep  are  considered  risk  factors  for  arterial  hypertension  and 
cardiovascular diseases. Edentulism, by decreasing retro-pharyngeal space, may 
favor  upper  airway  occlusion  during  sleep.  In  edentulous  subjects,  removing 
dentures during sleep may favor respiratory disorders, and increase the risk for 
hypertension and cardiovascular disease. 
Different studies demonstrate that oral health conditions and edentulism is strictly 
related  to  age,  education,  socio-economic  status,  ethnicity  and  smoking 
[Thorstensson and Johansson 2010; Wu et al. 2012; Kim et al. 2012; Brennan et 
al. 2008; Elani et al. 2012].
In  economically  developed  countries,  the  trend  of  edentulism  has  declined 
consistently.  In England and Wales, the prevalence of edentulism for the adult 
population  declined  from 37% in  1968  to  12% in  1998  [Kelly  et  al.  1998].  In 
Australia,  the  prevalence  of  edentulism for  the  adult  population  declined  from 
20.5% in  1979  to  8% in  2002.  Among  older  adults  aged  65  and  above,  the 
reduction for males was from 59.7% to 26.5% and for females was from 71.5% to 
40.3%  [Sanders  et  al.  2004].  Similarly,  in  the  United  States,  the  few  studies 
available on middle-aged and older adults have shown that edentulism in these 
age groups has been dropping for the past several decades. One study revealed 
that within the period of 1971 and 2001, for those in a low socioeconomic position 
(SEP), the prevalence of edentulism declined from 50% to 32% in adults age 55–
64 and 58–43% in age 65–74; the comparable declines for these age groups for 
individuals in a high SEP were 22–6% and 30–9%,respectively [Cunha-Cruz et al. 
2007]. A report conducted by the National Centers for Health Statistics using the 
National Health and Nutrition Surveys of 1988–1994 (NHANES III) and NHANES 
1999–2004 [Kim et al. 2012] found that the prevalence of edentulism declined in 
the United States over these two-time periods from 34% to 27% among adults 
aged 65 and older over  [BA et al. 2007].  Thanks to improvements in oral health, 
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the proportion of the population who are edentulous has declined over the past 20 
years  [Sanders et al. 2004]. However, the number of people requiring complete 
dentures has been predicted to increase over the next  20 years in the United 
States. Moreover, although implant treatment is reportedly increasing, the need for 
complete denture treatment is likely to remain substantial in the future rise [Starr 
and Hall 2009].
Musacchio et al. [Musacchio et al. 2007] reported the prevalence of edentulism in 
north-est of Italy was 43.8%; this was more pronounced in women and increased 
with age. It was 31.8% in the 65-69 years age group and more than twice (63.9%) 
in the 90/ years group. The prevalence of edentulous subjects was much higher in 
heavy smokers than in non-smokers (55.6% versus 26%) and in subjects with 0-3 
years of education (52.4%) than 4-8 years (44.3%) and >8 years (3.3%).
Douglass et al.  [Douglass et al. 2002] indicated that edentulism has declined by 
10%  every  decade  and  that  only  90%  of  edentulous  adults  obtain  and  wear 
complete dentures.  However,  when the  number  of  adults  in  each specific  age 
group  is  multiplied  by  the  percentage  who  need  a  complete  maxillary  or 
mandibular denture, the results suggest that the adult population in need of 1 or 2 
complete dentures will  increase from 33.6 million adults in 1991 to 37.9 million 
adults in 2020. The 10% decline in edentulism experienced each decade for the 
past 30 years will be more than offset by the 79% increase in the adult population 
older than 55 years. the number of people in the United States who need complete 
dentures will increase over the next 20 years despite an anticipated decline in the 
age-specific rates of edentulism.
The assumption that the most of edentulous persons wear  and utilize dentures 
was proven Redford et al  and Marcus et al.  [Redford et al. 1996; Marcus et al. 
1996] in  their  analysis  of  denture use in the United States and New England. 
These  2  research  groups  found  that  89.6%  [Redford  et  al.  1996] and  89.9% 
[Marcus et al. 1996],  respectively, of the edentulous population used dentures. 
For past  decades,  conventional  dentures were the only  available treatment for 
edentulism.  This  treatment  relies  on  the  retention  and  support  provided  by 
remaining bone ridge, but many denture-wearing patients have a poor diet and 
cannot speak clearly due to lack of denture retention and stability  [Sánchez-Ayala 
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et al. 2010].  Inevitable ridge resorption, at the onset of edentulism or over time, 
may further decrease oral function if dentures do not remain retentive and stable. 
Ill-fitting  dentures  can  prevent  enjoyment  of  food  and  affect  overall  nutrition 
[Marcus et al. 1996]. The success of conventional complete dentures treatment is 
variable and depends on a patient’s adaptive capacity to overcome the limitations 
of complete dentures by an habituation process. The inadequacy of conventional 
treatment makes implant therapy an alternative to provide significant improvement 
in stability, retention and quality of life in denture-wearing patients. [Sánchez-Ayala 
et  al.  2010].  Moreover  implant-supported  fixed  dental  prosthesis  could  be 
considered a restitutio ad integrum of oral health problems. 
The  introduction  of  osseointegrated  implants  has  opened  new  possibilities  for 
improving chewing capacity of edentulous subjects wearing removable dentures. 
In addition to fixed dental prosthesis, implants can also be used to improve the 
function of removable prosthesis by the use of various retention systems.
The  limit  of  implant  therapy  is  inadequate  quantity  of  bone:  resorption  and 
remodelling of the alveolar ridge is a process that occurs especially after tooth 
extraction and results in a decrease ridge dimension [Schropp et al. 2003; Araujo 
and Lindhe 2005]. The volume and rate of bone loss depends by different factors 
such  as  gender,  hormones,  general  disease,  denture  rehabilitation  and 
metabolism [Güler et al. 2005]. The greater amount of resorption occurs during the 
first 3 months of healing with a significative loss of height and width of the alveolar 
bone  [Schropp  et  al.  2003;  Kerr  et  al.  2008].  Horizontal  dimensional  changes 
consist of 50% alveolar ridge reduction after 1 year from tooth extraction [Schropp 
et  al.  2003].  The  resorption  occurs  primarily  from  the  buccal  aspect,  with 
significantly  less  resorption  from the  lingual  aspect  [Araujo  and  Lindhe  2005]. 
Alveolar ridge resorption is usually more rapid in the premolar and molar region 
than the anterior region af the mandible [AA 2002]. 
Furthermore after teeth extraction in the anterior mandibular region there is higher 
basal  bone  disponibility  and  there  are  not  anatomical  landmarks  to  be 
compromised  for  implants  insertion  such  as  in  the  maxillary  anterior  region. 
Oikarinen et al suggest that implants of 8mm or longer could be inserted in the 
anterior  maxilla  in  more  than  50%  of  patients.  The  mandible  showed  that 
implantation was possible in almost every jaw with fixture of 8mm or longer in the 
canine regions [Oikarinen et al. 1995]. Instead in the maxillary posterior region the 
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proportion of sites with bone height  ≥8mm and bone width  ≥6mm was 28.3%, 
18.4%, 8.0% and 18.2% at first premolar, second premolar, first molar and second 
molar sites, respectively [Pramstraller et al. 2011] The use of removable dentures 
significantly increases the severity of alveolar bone resorption in edentulous areas. 
Xie et al.  reported that the edentulous maxilla has a much greater reduction in 
radiologic  heights  compared  to  the  edentulous  mandible  for  both  sexes.  The 
finding is considered to be in agreement with the study of Tallgren [Xie et al. 1997; 
Tallgren 1972]. 
In addition to the problem of edentulism, Injuries caused by trauma, tumor or cyst 
resection, infectious diseases, and also congenital and developmental conditions 
(i.e.,  cleft  palate  de-  fects)  may  result  into  serious  functional,  aesthetical  and 
psychological sequelae  [Cohen 1995; Hunt and Hobar 2003]. In such situations, 
absence of hard and soft tissues can be disfiguring and often compromise basic 
functions  such  as  mastication,  speech,  swallowing,  and  also  lead  to  limited 
thermal  and  physical  protection  of  important  anatomical  structures  (i.e.  brain, 
nerves, arteries, veins) [Davis and Telischi 1994; Kadota et al. 2008; Curtis et al. 
1997; Urken et al. 1991]. The progression of certain oral conditions may also result 
in craniofacial defects of difficult resolution. For istance periodontitis is a chronic 
inflammatory disease of bacterial  etiology,  characterized by the loss of support 
around teeth, including alveolar bone resorption and soft tissue alterations [Genco 
1992; Kinane and Bartold 2007; Feng and Weinberg 2006].
Achieving  predictable  regeneration  in  the  treatment  of  craniofacial  defects  is 
remarkably challenging in most clinical scenarios
Another  current  cause  of  bone  resorption  is  peri-implantitis.  Peri-implantitis  is 
defined as inflammation of peri-implant tissues accompanied with changes in the 
level  of  crestal  bone  and  with  the  presence  of   bleeding  on  probing  and/or 
suppuration, with or without concomitant deepening of peri-implant pockets [Lang 
et al. 2011].
Peri-implantitis is a serious current problem because neither the causes neither 
therapies are currently unclear.
However, this disease will be discussed in the next chapter
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Regenerative procedures, applying the concept of guided bone regeneration, use 
of  bone  grafts,  and  membranes,  are  implemented  to  rebuild   peri-implant 
supporting bone, rebuild bone after implant-extraction for peri-implant inflammation 
and for alveolar ridge regeneration. 
Tooth anatomy
Each tooth consists of three main parts: the crown, the neck and the root, that we 
can define with anatomic o clinical criteria. Here follow a brief review of the tooth 
anatomy (Figure 3) involved on stem cells-tissue engineering field.
Dentin
Dentin is a mesenchymal derived tissue lying between enamel or cementum and 
dental pulp (pulp chamber and root canal). It is a mineralized connective tissue 
with  an  organic  matrix.  It  is  made  up  of  70%  inorganic  materials  (especially 
hydroxyapatite crystals),  20% organic materials and 10% water by weight.  The 
bulk of organic matrix (85-90%) consists of type I collagen, there is also a minor 
amount of type V and VI collagen. Noncollagenous molecules of dentin are dentin 
phosphorines,  Gla  proteins,  acidic  glycoproteins,  growthrelated  factors,  serum 
derived proteins, lipids and proteoglycans. Dentin has microscopic channels (0,5-3 
Figure 3: tooth anatomy
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μm), called dentinal tubules, radiating outward from pulp cavity to dentinoenamel 
or dentino-cementum junction. These tubules contain projections of cells secreting 
dental matrix, known as odontoblasts. The most peripheral aspect of the pulp is 
lined by the body of these odontoblasts [Yoshiba et al. 2002]
Pulp
Pulp consists of a loose connective tissue enclosed by rigid predentin and dentin. 
Along the border between the dentin and the pulp are odontoblasts. The thickness 
of dentinal layer increases with age due to the deposition of secondary and tertiary 
dentin, reducing the volume of the pulp chamber and the root canals. The most 
peripheral aspect of the pulp contains four layers of cells: the odontoblastic layer 
(the  most  external  one),  the cell-free  zone,  the  cell-rich zone and the  parietal 
plexus of nerves. Deep inside is the pulp proper, composed of a great amount of 
fibroblasts and ECM. Blood vessels and nerves enter the tooth mostly through the 
apical foramen. Other cells in the pulp include undifferentiated mesenchymal cells, 
deriving from dental papilla, fibrocytes, macrophages and lymphocytes.
Alveolar bone
The  bone  that  supports  the  teeth  is  called  alveolar  bone.  It  is  composed  of 
compact bone and trabecular or spongy bone. The outside wall  of the bone is 
compact bone, such as the thin layer that lines the socket known as lamina dura.
The spongy bone is inside and contains bone marrow. The number and the size of 
the trabeculae in this bone are determined by the function activity of the organ.
Alveolar bone proper is the part just around the tooth and it gives attachment to 
the PDL fibres (bundle bone). The alveolar bone proper is also called cribiform 
plate, due to the presence of perforation for the entry of vessels and nerves.
Bone is made of 65% inorganic material (mainly hydroxyapatite) by weight, 15% 
water, 20% organic material. The organic matrix is composed of collagen type I 
(90-95%),  Gla  proteins,  glycoproteins,  phosphorines,  proteoglycans,  growth 
factors and bone morphogenetic proteins (e.g. osteogenin) [Lindhe et al. 2009a].
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Odontogenesis
During the sixth week of embryogenesis, after the migration of neural crest cells 
into head and neck mesenchyme, the ectoderm of the first brachial arch begins to 
proliferate giving rise to the vestibular lamina and the dental lamina.
Dental lamina is a band of ectodermic cells growing from the epithelium of the 
stomodeum into the underlying mesenchyme and giving rise to the enamel organs 
of teeth, along the horse shoe shaped dental arches.
Several  transcription  factors  are  implicated  in  odontogenesis,  including  Pax9, 
Pitx2, Runx2, Msx1, Msx2, Bmp2, Bmp4, Fgf8 and Fgf9 [Bei and Maas 1998]. The 
development is commonly divided into the following stages: the bud stage, the cap 
stage,the bell stage.
The early bell stage of odontogenesis is characterized by epithelial expansion and 
differentiation into the inner and outer enamel epithelium, stratum intermedium and 
stellate reticulum.
During the late bell stage, two tooth specific cell types are formed: ameloblasts, 
which  derive  from  the  inner  enamel  epithelium  and  produce  enamel,  and 
odontoblasts, which differentiate from dental papilla and synthesize dentin.
Dentinogenesis starts before enamel formation with the secretion of an organic 
matrix  in  the  area  directly  adjacent  to  the  inner  enamel  epithelium.  Dentin  is 
formed  by  the  production  of  organic  matrix  (predentin)  and  the  simultaneous 
mineralization of this matrix [Hao et al. 2009].
After crown formation, root development begins. The cells of the inner and of the 
outer enamel epithelium become in contact and give rise to the cervical loop at the 
base of enamel organ.
The cells of the cervical loop continue to grow away from the crown and become 
Hertwig’s epithelial  root sheath. It  induce the adjacent cells of dental papilla to 
differentiate into odontoblasts and produce dentin. Once this structure fragments, 
the dentin of the root comes in contact with the dental follicle and stimulates the 
cementoblasts to begin cementum secretion.
The dental follicle also gives rise to the other supporting structure of the tooth: the 
periodontal ligament and the alveolar bone proper [Luan et al. 2006].
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Bone tissue 
Bone tissue is a connective tissue specialized in providing support. Affinity of bone 
tissue with connective tissues is confirmed by both its origin from mesenchyme, 
the embryonic tissue where connective tissues is derived from, and its composition 
since  the  extracellular  matrix  is  made  up  of  collagen  fibers  and  amorphous 
fundamental substance.
Bone tissue is characterized by mineralization. The presence of minerals and the 
peculiar distribution of organic components in the extracellular matrix lend to this 
tissue remarkable mechanic properties: hardness, resistance to pressure, traction 
and torsion. Thanks to these properties, bone tissue represents an ideal material  
for the formation of skeletal bones, which as a whole can be seen as a supportive 
scaffolding of the organism. Furthermore, given the relevant amount of calcium 
salts, bone tissue represents the principal store of calcium ions for the metabolic 
needs of the entire organism.
Calcium deposition in the bone and its mobilization, finely controlled by endocrine 
mechanisms, provide a crucial contribution to the regulation of plasma levels of 
this ion.
Morphology of bone tissue 
From a macroscopic point  of view, two varieties of bone can be distinguished: 
compact bone and spongy bone (Figure 4)
Compact bone
Compact  bone  is  found  in  the  outer  layer  of  short,  flat  and  long  bones  and 
constitutes the diaphysis of the latter as well.
The bone matrix of the compact bone is organized in lamellae which form cavities 
named  bone  lacunae  containing  osteocytes.  Compact  bone  lamellae  usually 
arrange themselves in three different ways:
- Concentrically around vascular channels to form cylindrical structures, na-
med  Haversian systems or  osteons, oriented along the major axis of the 
bone;
- In the spaces around osteons, taking on various dimensions and irregular 
shapes, to form interstitial systems ;
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- Under the periosteum (a layer of connective tissue on the outer surface of 
the bone) and over the endostium (connective tissue on the inner surface of 
the bone) to form inner and outer circumferential lamellae.
In the compact bone two categories of vascular channels can be identified:
- Harvesian  canals:  longitudinal  canals  located  at  the  center  of  osteons 
containing one or two vessels;
- Volkmann’s canals: transverse canals interconnecting Harvesian canals
Spongy bone
Spongy bone can be found primarily inside short bone, flat bones and epiphysis of  
long bones.
It  is  made  up  by  a  tridimensional  network  of  branched  bone  spicules  named 
trabeculae, that limit a labyrinth of interconnected spaces occupied by hemopoietic 
bone marrow.
Figure  4: Distribution  of  compact  and 
spongy bones in the bone.
Bone extracellular matrix
Being a connective tissue,  bone tissue contains  a  relevant  amount  of  organic 
extracellular  matrix,  composed  of  connective  fibers  and  amorphous  substance 
enriched by the mineral component.
Organic matrix
It favors resistance to traction and pressure. It consists of:
- connective fibers: almost totally made up of Type I collagen fibers, are cha-
racterized by a great number of crossed bundles that maintain united the si-
gle molecules of tropocollagen. The abundant presence of collagen is the 
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main cause of the marked acidophilia that  characterizes the intracellular 
substance of the bone.
Collagen fibers aggregate to  form remarkably thick collagen fibers (5-10 
µm) only in the fibrous bone tissue, whereas in the lamellar bone tissue col-
lagen  microfibrils  group  to  form a  homogeneous tridimensional  network. 
Connective  fibers  are  particularly  abundant  in  the  periosteum therefrom 
thick bundles of collagen fibers start to penetrate into the cortical bone tis-
sue and get lost in the intracellular substance of the bone. These bundles 
constitute  Sharpey’s perforating fibers, which fasten the periosteum to the 
surface of the bone.
- elastic fibers: virtually absent from the bone tissue, reticular fibers are loca-
ted at the level of the basal membrane that surrounds intraosseous blood 
vessels;
- amorphous substance: characterized by a peculiar and relevantly different 
composition in respect to other connective tissues, it is composed of va-
rious macromolecules:
 Proteoglycans: made up of sulfated glycosaminoglycan acids (chera-
tan sulfate, chondroitin sulfate) which are kept together by short pro-
tein chains.
o Glycoproteins: include several molecules, some of which are belie-
ved to play a fundamental  role in the mineralization processes. 
Among these:
a) Osteonectin: the most abundant protein. It possesses high af-
finity for calcium, both as a free ion and as an associated ion 
in crystal-like complexes. It is believed that it works as nuclea-
tion agent for mineral crystals since it is considered capable of 
concentrating  calcium located nearby, thus creating the con-
ditions to start the precipitation of calcium phosphatase.
b) Fibronectin: is an adhesion molecule located primarily in the 
pericelluar matrix and characterized by a portion capable of 
binding with collagen. It is believed that fibronectin is involved 
in the following processes: migration, adhesion to the matrix 
and organization of the bone cells.
c) Alkaline phosphatase:  is an enzyme capable of hydrolyzing 
phosphate groups of organic substrates in a basic  environ-
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ment. It is involved in the processes of mineralization, provi-
ding phosphate ions to form mineral crystals.
o Sialoproteins  (BSP):  specific  glycoproteins  containing  traces  of 
sialic acid which possess the RGD (Arg-Gly-Asp) aminoacid se-
quences responsible for the adhesion of the cells to the bone ma-
trix. They include osteopontin.
o Proteins containing gamma linolenic acid (GLA): thanks to GLA 
they are able to chelate bivalent cations such as calcium ion. Two 
proteins containing GLA can be identified in the bone:
a) Osteumcalcin: a small protein containing 3 or 5 GLA residues. 
It is involved in the inhibition of the matrix mineralization since 
it binds calcium ions and makes them available for the combi-
nation with phosphate ions thus inhibiting the dimensional gro-
wth of crystal minerals. It is abundant in the mature bone tis-
sue whereas is scarce in the developing bone tissue (osteoid 
tissue).
b) GLA protein  of  the matrix:  it  has  a higher  molecular  weigh 
than osteumcalcin and can be found both in the mature bone 
and in the osteoid tissue as well as in the cartilage which is 
about to be replaced by osseous tissue.
Inorganic matrix
The mineral component represents 65% of the dry weight of the bone.
Its function is to provide hardness and rigidity to the bone tissue.
It  is made up of calcium crystals - mainly calcium phosphate -  and of calcium 
carbonate,  calcium  fluoride  and  magnesium  phosphate  in  smaller  quantities. 
Calcium phosphate  can be found in  the form of  apatite  crystals  (Ca10(PO4)62+) 
whose positive charges are normally neutralized by the binding with two hydroxide 
ions thus forming hydroxyapatite.
Hydroxyapatite crystals appear like long and thin needles about 2 nm thick and 20-
40  nm  long.  They  tend  to  arrange  themselves  parallel  to  each  other  and  to 
collagen microfibrils, covering their surface and permeating their porosities.
During the mineralization process of the bone, calcium phosphate precipitates at 
first in the form of tiny amorphous aggregates.
These initial nuclei of mineral concretion are rapidly replaced by very thin crystals 
positioned parallel  to  the  filamentous molecules  of  the  fundamental  substance 
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called axial filaments.These crystals assume the typical shape of apatite crystals, 
progressively  occupying  most  space  inbetween  collagen  microfibrils  and 
permeating the microfibrils themselves. Once the apatite crystals have formed, the 
deposition of new mineral can occur both through the formation of new crystals 
and  through  apposition  on  pre-existing  crystals.  This  phenomenon  is  finely 
regulated by bone cells thanks to the production of specific molecules of the bone 
matrix.
Bone cells
Four types of cells can be identified in the bone tissue: 
Osteoprogenitors (also  called  pre-osteoblasts),  osteoblasts,  osteocytes and 
osteoclasts.  Among these,  osteoprogenitors,  osteoblasts and osteocytes are in 
fact subsequent functional phases of the same cell type and are derived from the 
pluripotent  mesenchymal  cell  of  connective  tissues.  Osteoclasts,  instead,  are 
derived from precursors migrated from the blood to the bone tissue, the so called 
pre-osteoclasts, which are derived from the stem cells of the hematopoietic bone 
marrow.
Osteoprogentitor cells
Pre-osteoblasts  have  a  spindle  or  oval  shape,  a  dispersed  chromatin  nucleus 
(euchromatic)  with  a  large  nucleolus  and  scarce  and  basophilic  cytoplasm 
because  of  the  presence  of  a  number  of  free  polyribosomes,  whereas  other 
granules are scantily represented.
Osteoprogenitor cells place themselves on the free surfaces of the bones: the can 
be recognized at level of the inner layer of the periosteum, the so called Ollier’s 
osteogenic  layer,  rich  in  vessels  and  at  the  level  of  the  endostium  close  to 
capillaries.
Osteoprogenitor cells are able to proliferate, a feature which is shown especially 
when their body is growing but can be observed also during adult life. They can 
produce  and  secrete  growth  and  differentiaton  factors,  the  so  called bone 
morphogenetic  proteins (BMP).  When  they  start  the  differentiation  process, 
osteoprogenitor cells change into osteoblasts.
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Osteoblasts
Osteoblasts are primarily responsible for synthesizing the extracellular bone matrix 
and for its mineralization. They have a spherical or polyhedric shape and tend to 
align to form epithelious laminae by the developing bone surfaces. In the active 
phase of the deposition of the bone matrix, osteoblasts have relevant dimensions 
(about  20  µm),  a  euchromatic  spherical  nucleus  with  a  large  nucleolus,  a 
basophilic abundant cytoplasm with PAS-positive granulations, a well-developed 
Golgi’s  apparatus and a number of  long-shaped mitochondria.  Osteoblasts are 
characterized by the positivity for alkaline phosphatase and by the presence of 
small cytoplasmatic granules pink in colour containing the precursors of the bone 
matrix glycoproteins. On the  side facing the mineralizing bone matrix, they show 
several  vescicles  rich  in  proteoglycan  which,  once  expelled,  will  form  the 
mineralization nuclei.
Osteoclasts are interconnected with each other and with nearby osteocytes by 
means of gap junctions to exchange signal molecules which coordinate metabolic 
activity and bone matrix deposition.
Osteocytes
Osteocytes  are  cells  which  are  typically  present  in  the  mature  bone  and  are 
responsible for its maintenance and turnover. They are terminal cells with a finite 
lifespan.
An osteocyte is a star-shaped cell, with a cellular body resembling a biconvex lens 
and with several cytoplasmatic extensions.
It  presents  a  heterochromatic  nucleus  (with  condensed  chromatin)  a  small 
nucleolus  and  a  perinuclear  cytoplasm  rather  scarce  and  basophilic. 
Cytoplasmatic  organules,  RER  and  Golgi’s  apparatus  tend  to  decrease  their 
dimension as the cell grows older until it dies due to apoptosis.
In the bone tissue, the osteocyte is enclosed in a niche carved in the bone matrix, 
called bone lacuna, whose shape replicates that of the cell, whereas its extensions 
reach thin canals called bone canaliculi.
Each osteocyte is in contact with surrounding osteocytes through gap junctions at 
the  extremities  of  their  extensions.  Water  and  metabolites  can  reach  all 
osteocytes, even the farthest away from blood vessels, through non-mineralized 
osteoid  tissue  which  covers  the  inner  communicating  surface  of  lacunae  and 
canaliculi. Moreover, metabolites and signal molecules dissolved in the cytoplasm 
can be exchanged between osteocytes through the gap junctions.
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Osteoclasts
Osteoclasts  are  cells  specialized  in  bone  resorption.  They  derive  from  pre-
osteoclasts originating in the hematopoietic bone marrow and are carried by the 
blood  stream  up  to  the  sites  of  bone  resorption,  where  they  melt  together 
generating  active  osteoclasts,  i.e.  syncytial  elements  capable  of  dissolve  and 
digest organic components of the bone tissue.
Mature osteoclasts are giant  plurinucleated cells  (100-200 µm) with acidophilic 
cytoplasm;  in  a  single  osteoclast  can  be  detected  up  to  50  nuclei  with  lax 
chromatin and clearly visible nucleolus. When a osteoclasts is activated it adheres 
to the mineralized matrix and due to its erosive action a cavity called  Howship’s 
lacuna is formed. The side of the cell which is clinged to the bone is characterized 
by the so called ruffled border, a thickening of the cell surface made up of a large 
number  of  cytoplasmatic  lamellae,  having  different  sizes  and  lengths,  which 
considerably widen the extension of the plasmalemma.
Through the ruffled border osteoclasts adhere tightly to the surface of the bone to 
be resorbed, delimiting the extracellular environment where ostoelytic substances 
are released, an area called sealing zone.The resorbtion of the bone matrix begins 
with  the  dissolution  of  the  mineral  component  due  to  the  acidification  of  the 
microenvironment  in  the  sealing  zone,  followed  by  exocytosis  of  lysosomal 
enzymes which digest the organic components of the bone matrix. Furthermore, 
osteoclasts  stimulate  osteobalsts  to  release  collagenase  enzyme  which 
contributes, through its lytic activity, to the digestion of the organic matrix of the 
bone. Once the first lacuna has been formed, the osteoclast separates from the 
bone matrix and migrates with amoeboid movement to a portion of an adjacent 
bone, adhering again and forming a new lacuna. Osteoclastic function is finely 
regulated by hormonal and local factors.
Bone histogenesis
Bone always develops replacing a pre-existing tissue,  be it  mesenchyme or  a 
differentiated connective tissue. The processes which lead to the genesis of the 
bone tissue within another tissue are called ossification or osteogenesis.
These processes are maximized during prenatal life and continue to maintain a 
high pace throughout the period of the somatic development.
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Two types of ossification can be identified:
- Direct or intramembranous ossification;
- Indirect or chondral ossification.
Direct ossification
Direct  or  intramembranous  ossification  is  typical  of  flat  bones.  It  starts  from 
ossification centers which develop in the mesenchyme at early stages of foetal life 
or in membranes of fibrous, dense connective tissue derived from mesenchyme at 
later stages of intrauterine and postnatal life.
Direct  ossification  begins when,  beside  a  rich vascular  network,  mesenchymal 
cells differentiate into osteoprogenitor cells which, in turn, change into osteoblasts.
Through gap  junctions osteoblasts  align  themselves in  epithelial-like  rows  and 
start  depositing  the  organic  matrix  of  the  bone,  i.e.  osteoid  tissue.  When  the 
osteoid  tissue  undergoes  mineralization,  it  changes  into  spongy  bone  and 
osteoblasts  remain  enclosed  in  bone  lacunae  transforming  into  osteocytes. 
Afterwards preosteoclasts differentiate  into  osteoclasts  which dissociate fibrous 
bone, later replaced by lamellar bone.
Indirect ossification
Indirect or chondral ossification is the most widespread variant. Typically, the bone 
is  preceded  by  a  cartilage  scaffold  with  about  the  same  shape  of  the  bone 
segment to be and which is later reabsorbed and replaced by bone tissue. Bone 
can develop both inside the cartilage scaffold (endochondral ossification) and on 
the outer surface of the cartilage in contact with the perichondrium (perichondral 
ossification).
Perichondrial ossification starts in the perichondrium where osteoprogenitor cells 
differentiate into osteoblasts which deposit osteoid tissue. This tissue is committed 
to become fiber bone through mineralization and is later rearranged by osteoclasts 
with subsequent deposition of lamellar bone. The bone thus generated binds to 
the surface of the cartilage,  under the perichondrium which then develops into 
periosteum.
Endochondrial ossification starts when the chondrocytes of the cartilage scaffold 
undergo hypertrophy. In their cytoplasm drops of glycogen accumulation and PAS-
positive granulations resembling the calcifying globules of the osteoclasts can be 
detected. They release vesicles inducing the calcification of the cartilage matrix 
and, finally, are destined to undergo apoptosis.
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Calcified cartilage matrix is partially subject to erosion thanks to the intervention of 
cells  of  osteoclastic  nature,  coming from the nearby already-formed bone and 
generating wide cartilage lacunae which merge into each other and where blood 
vessels,  departing  from the  perichondrium and  accompanied  by  mesenchymal 
cells,  penetrate.  Mesenchymal  cells  differentiate  into  osteoprogenitor  cells  and 
afterwards  in  osteoblasts  which  deposit  fibrous  bone  by  the  remnants  of  the 
calcified  cartilage matrix.  Finally,  osteoclasts  intervene to  resorb both  the fiber 
bone and the mineralized bone matrix, whereas new osteoblasts deposit lamellar 
bone. Some of the mesenchymal cells, penetrated with blood vessels, originate 
new vessels and hematopoietic bone marrow. [Zallone 2007; Capitani et al. 1996]
Implant therapy
Missing teeth and supporting oral  tissues have traditionally  been replaced with 
removable dentures or fixed bridges permitting restoration of masticatory, phonetic 
function, and aesthetics.
Replacement  of  lost  dentition  has been traced to  ancient  Egyptian  and South 
American civilizations. In ancient Egyptian writings implanted animal and carved 
ivory teeth were the oldest examples of primitive implantology. In eighteenth and 
nineteenth century England and colonial America, poor individuals sold their teeth 
for extraction and transplantation to wealthy recipients. The clinical outcomes of 
these transplanted dentitions were either ankylosis or root resorption. Continued 
research  prolonged  allotransplant  survival  but  did  not  appreciably  improve 
predictability.
In  1809  Maggiolo  placed  an  immediate  single-stage  gold  implant  in  a  fresh 
extraction site  with  the  coronal  aspect  of  the  fixture  protruding  just  above the 
gingiva.  Postoperative  complications  included  severe  pain  and  gingival 
inflammation.  Since  then  various  implant  materials  were  used  ranging  from 
roughened lead roots holding a platinum post to tubes of gold and iridium. Adams 
in  1937  patented  a  submergible  threaded  cylindrical  implant  with  a  ball  head 
screwed to the root for retention for an overdenture in a fashion similar to that 
done today.
Up to this point implant success was marginal with a maximum longevity of only a 
few years.  Strock placed the first  long-term endosseous implant  at  Harvard in 
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1938. This implant was a threaded cobalt-chrome-molybdenum screw with a cone-
shaped head for the cementation of a jacket crown. The implant remained stable 
and asymptomatic until  1955, at  which time the patient died in a car accident.  
Strock  wrote,  “The  histological  sections  of  implants  in  the  dog  study  showed 
remarkable complete tolerance of the dental implant and the pathologist report so 
indicated to our gratification.” Strock demonstrated for the first time that metallic 
endosteal dental implants were tolerated in humans, with a survival rate of up to 
17 years.
Due to inadequate alveolar bone height in certain sites of the jaws, subperiosteal 
implants were developed. In 1943 Dahl placed a metal structure on the maxillary 
alveolar crest with four projecting posts.  Multiple variations to this initial  design 
were  fabricated  but  these  devices  often  resulted  in  wound  dehiscence.  Blade 
implants were introduced by Linkow and by Roberts  and Roberts.  There were 
numerous configurations with broad applications,  and the implants became the 
most widely used device in implantology in the United States and abroad.
A two-staged  threaded  titanium root-form implant  was  first  presented in  North 
America by Brånemark in 1978. He showed that titanium oculars, placed in the 
femurs  of  rabbits,  osseointegrated  in  the  femurs  of  rabbits  after  a  period  of 
healing.
Two-staged titanium implants were first  placed in patients in 1965 and studies 
showed  prolonged  survival,  free-standing  function,  bone  maintenance,  and 
significant  improvement  in  benefit-to-risk  ratio  over  all  previous  implants.  This 
breakthrough  has  revolutionalized  maxillofacial  reconstruction.  Subsequently, 
various implant  designs have been manufactured and research in implantology 
has grown exponentially. The frontiers of implantology are rapidly being advanced 
and esthetics continue to be an integral part of this progress  [Brånemark et al. 
1985].
In  1977,  Brånemark  presented  his  research  work  carried  out  over  10  years 
showing  that  bone  can  grow  intimately  onto  the  surface  of  titanium  implants 
(Brånemark 1977). The now well-accepted concept, termed osseointegration, has 
undoubtedly been one of the most significant scientific breakthroughs in dentistry 
over the past 30 years. A multitude of implant designs have been marketed since, 
and the clinical situations in which osseointegrated implantretained prostheses are 
used have expanded enormously.
One  of  the  key  factors  for  the  long-term  success  of  dental  implants  is  the 
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maintenance of healthy tissues around them. A cause-effect relationship between 
bacterial plaque accumulation and the development of inflammatory changes in 
the soft  tissues surrounding dental  implants has been shown  [Pontoriero et al. 
1994]. If this reversible condition, called ’peri-implant mucositis’, is left untreated, it 
may lead to the progressive destruction of the tissues supporting an implant (peri-
implantitis) and ultimately to its failure. [Mombelli 1999] [Esposito et al. 2011]
The 20-year cumulative survival rates of short and standard implants were 92.3 
and 95.9%, respectively. The cumulative success rates were 78.3 and 81.4%. The 
survival rates of short implants in posterior and anterior regions were comparable: 
95 and 96.4%, respectively.[Lops et al. 2012]
Implant therapy nowadays is a major branch of dentistry that is constantly evolving 
also thanks to the scientific interest of many companies. The patients themselves 
requiring implant  therapy to get  a fixed prosthesis that mimics the most of  the 
natural tooth (Figure 5,  Figure 6). Implant therapy can also be used to stabilize 
dentures and thus ensuring greater comfort to the patient both masticatory that 
phonetic and aesthetic (Figure 7).
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Figure 7: patient before and after treatment
Peri-implantitis 
Implant therapy is a well established method of replacing missing teeth. Excellent 
long- term results can be achieved, but biologic complications may occur.
The  most  common  biological  complications  were  hygiene-related:  30.2%  of 
patients displayed peri-implant mucositis and 10.4% peri-implantitis  [Francetti  et 
al. 2013]. 
Perimplantitis  is  defined  as:  plaque-induced  progressive  marginal  bone  loss 
observed on radiographs with clinical  signs of  infection of  the peri-implant soft  
tissues (Figure 8).
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Figure  8: patient with severe peri-implantitis: presence of suppuration and bone 
loss
The  occurrence  of  peri-implantitis  is  not  rare.  In  a  single-cohort  study  [Roos-
Jansåker et al. 2006] peri-implantitis, defined as a marginal bone loss of 3 mm or 
more in combination with bleeding on probing or pus or both, was diagnosed in 
16% of patients treated with turned (machined) Brånemark implants 9 to 14 years 
after loading. The occurrence of peri-implantitis around implants with roughened 
surfaces is likely to be even higher, since it was observed in another Cochrane 
systematic review  [Esposito et al.  2007] that statistically significantly more peri-
implantitis occurred at 3 years of loading around implants with roughened surfaces 
when compared to turned (machined) Brånemark implants  [Esposito et al. 2011].
In a recent consensus conference Klinge et Meyle reported the prevalence of peri-
implantitis over a 5-10 year period following implant placement has been in the 
order of 10% of implants and 20% of patients [Klinge et al. 2012].
Cecchinato showed that during the 10-year follow-up period, 12% of patients and 
5% of implants displayed signs of peri-implantitis (bone loss >0.5 mm, BoP+, PPD 
≥6 mm) [Cecchinato et al. 2013].
Keratinized gingiva has been shown to promote soft tissue health around teeth. 
However, around dental implants, the presence of keratinized gingiva may or may 
not  be  important  for  preservation  of  crestal  bone.  Krekeler  and  colleagues 
suggested that  there is a  strong correlation of  keratinized gingiva with  implant 
failure and the absence of an adequate band of keratinized mucosa surrounding 
the  abutment.  This  suggested  relationship  was  based  on  the  ability  of  the 
keratinized mucosa to withstand bacterial insult and ingression, which can lead to 
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peri-implantitis [Krekeler et al. 1985].
The keratinized gingiva allows a better marginal seal, mantaining a mucosal collar 
that prevents the access of bacteria into the underlying tissues. These bacteria 
can maintain inflammatory conditions harmful  to the peri  implant  soft  and hard 
tissues. The Brito’s systematic review concludes that the presence of an adequate 
zone of keratinized tissue may be necessary because it was shown to be related 
to better peri-implant tissue health [Brito et al. 2013].
From studies of Lang, Lindhe and Schou conducted on animal models in which 
they were created peri-implantitis and experimental periodontitis, is evident that to 
support peri-implant pathology plaque is a key factor. Plaque is a biofilm rich in 
bacteria. The bacteria around teeth and implants have very similar characteristics: 
sites  showing  periodontal  and  peri-implant  inflammation  with  diffuse  biofilms, 
contain a significant amount of gram-negative bacteria.
The  main  treatment  of  peri-implantitis  is  based  on  the  resolution  of  the 
inflammatory lesion. In experiments on animals conducted by Ericsson, Persson 
and  Lindhe,  peri-implant  experimentally  induced  lesions  were  subsequently 
subjected to therapy. The animals were administered systemic antibiotics, while 
the local treatment was performed only on some of the implant sites affected. After 
several months of healing, the implant sites were also receiving local therapy, ie 
the subgingival mechanical cleaning, inflammatory lesions had resolved, While in 
non-exposed  to  local  treatment  sites  had  been  maintained  the  inflammatory 
infiltrate in the mucosa and bone.
Peri-implantitis antibiotics treatment must be combined with a meticulous removal 
of biofilm from contaminated implant surface.
To  conclude  it  can  be  stated  that  lesions  caused  by  peri-implantitis  are  little 
encapsulated, extend inside the marginal bone tissue and can, if left to progress, 
lead  to  loss  of  the  implant.  Symptoms  of  peri-implantitis  are  related  to 
infectious/inflammatory  lesion.  Therefore  you  are  having  radiographic  signs  of 
bone loss, which looks lijke a crater. Swelling and redness of the mucosa occur 
with frequency, but also bleeding after slight probing and suppuration. However 
the implant  may still  remain stable  for  extended periods of  time  [Lindhe et  al. 
2009b].
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Bone regeneration
Autogenous tissues have been widely used and are still considered as the gold 
standard to which all  other biomaterials  are compared  [Dimitriou et  al.  2011a]. 
Nevertheless,  even  the  most  advanced  reconstructive  techniques  using 
autologous  materials  are  often  insufficient  to  restore  extensive  or  complex 
maxillofacial  defects  [Susarla  et  al.  2011].  Autografts  contain  all  of  the  basic 
elements  necessary  to  induce  effective  tissue  regeneration,  provided  cells, 
extracellular matrix and cytokines [Pape et al. 2010; Khan et al. 2005]. However, 
the use of autogenous tissue involves the need of harvesting it from a donor site,  
with  the  consequent  drawbacks  in  terms  of  costs,  procedure  time,  patient 
discomfort and possible complications.
Additionally, oftentimes the volume of harvested tissues is not sufficient to fill or 
cover a defect, given the limited availability of autogenous tissues [Dimitriou et al. 
2011b;  Zouhary  2010].  To  overcome these  limitations,  a  variety  of  exogenous 
substitute  materials,  including  allografts,  xenografts  and  alloplasts,  have  been 
introduced in clinical practice over the last three decades  [Bauer and Muschler 
2000; De Long et al. 2007]. These materials primarily act as scaffolds, supporting 
the  migration  of  cells  from the  periphery  of  the  grafted  area.  Substitutes  are 
indicated in the treatment of cases where the application of autografts alone may 
not  be  possible  [Finkemeier  2002].  Unfortunately,  when  comparing  these 
biomaterials to autografts other limitations emerge.
The presence of cellular populations, orchestrate the release of growth factors, 
maintenance of  a  stable  scaffold,  and  stimulate  angiogenesis  and  are  key for 
successful  tissue regeneration as they play a fundamental  role  on the healing 
process [Taba et al. 2005]. Controlling the dynamics of these elements allows for a 
more predictable treatment of challenging alveolar bone loss or extremily atrophy.
Novel  tissue  engineering  therapies  aimed  at  enabling  clinicians  to  achieve 
predictable regeneration have been recently developed.
Tissue engineering has a great potential in the clinical area for the regeneration of 
both hard and soft  tissues and could represent  a  new important  instrument to 
enhance wound healing in different scenarios.
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Tissue engineering
The  great  progress  in  the  knowledge  in  the  field  of  cellular  biology  and  of 
biotechnologies has led to the development of technologies aimed at the  in vitro 
growing and reconstruction of tissues or organs, thus defining a new branch of 
biomedical  sciences  known  as  tissue  engineering.  The  combination  of  these 
technologies make possible the  ex vivo expansion of autologous cells and their 
employment in the repair of lesions and in the regeneration of tissues through the 
use  of  biocompatible  three-dimensional  matrices.  By  suitably  modulating  the 
chemical, mechanical and physical characteristics of such matrices, it is possible 
to  use  them  as  supports  for  the  inoculation,  growth  and  differentiation  of 
autologous cells for the in vitro regeneration of specialized tissues.
Tissue engineering allows to combine the potentials of living cell transplantation 
with the technology of artificial organs for the realization of functional structures. 
For this reason, tissue engineering, with the introduction of bioartificial structures, 
represents  an  evolution  with  respect  to  the  substitutes  of  first  generation: 
traditional  artificial  organs  like  heart  valve  prostheses,  pacemakers  and 
orthopaedic  prostheses,  whose  clinical  alternative  was  represented  by  the 
transplantation of organs from donors. 
The in vitro reconstruction of a tissue or of a whole organ, however, requires not 
only an in-depth study of the composition and structure of the three-dimensional 
matrices,  but  also  of  the  physical  forces acting  on it.  Furthermore,  it  requires 
knowledge about the chemical and molecular factors that regulate the growth and 
differentiation of cells and tissues.
Therefore, it  can be reasonably stated that tissue engineering is based on two 
main components:  three-dimensional support and biological component. The 
three-dimensional support is represented by biomaterials, whereas the biological 
component comprises both the cells and the molecular factors.
Biomaterials
A biomaterial is the three-dimensional support necessary for cells to be distributed 
in the three dimensions and to lay the extracellular matrix. Therefore, a biomaterial 
is  an  element  or  a  combination  of  several  elements  used  in  the  treatment, 
improvement or replacement of a tissue or of a whole organ.
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Biomaterials,  in  order  to  be  suitable  for  tissue engineering,  must  possess  the 
following characteristics:
- Biocompatibility with the receiving tissue or organ;
- Biodegradability: the ideal degradation speed corresponds to the speed of 
formation of the new tissue;
- Non-toxicity;
- Non-immunogenicity;
- Optimal mechanical properties to be inserted in the surrounding tissue;
- Suitable porosity and morphology for the transport of cells, gases, metabol-
ites, nutrients and molecules both within the biomaterial and between the 
biomaterial and the surrounding environment.
In  general,  biomaterials  are  designed  and  built  drawing  inspiration  from  the 
extracellular matrix, as this guarantees communication between the cells and the 
stability  of  the  tissues  by  means  of  the  adhesion  molecules.  In  general,  the 
extracellular matrix is made up of the ground substance, a very hydrous gel that 
provides  the  matrix  with  compressive  strength,  of  fibres  that  provide  tensile 
strength,  and  of  water  that  favours  the  rapid  diffusion  of  substances.  These 
elements, common to all extracellular matrices, are combined with different ratios 
in each tissue. Natural, synthetic or semi-synthetic biomaterials were used in order 
to obtain three-dimensional structures compatible with the extracellular matrix of 
the  tissue  to  be  regenerated.  Natural  biomaterials  are,  for  example,  collagen, 
gelatin,  fibrin,  hyaluronic  acid,  cellulose,  chitin,  alginates,  hydroxyapatite  and 
materials from cadavers or from animals. They provide several advantages, such 
as  selective  adhesion  (collagen),  biodegradability  (gelatin  and  chitin)  and 
mechanical properties similar to those of natural tissues (heart valves and blood 
vessels from animals). Natural biomaterials have some disadvantages as well: the 
possibility to transmit viral infections, antigenicity and instability. On the other hand, 
synthetic  biomaterials  are:  polyglycolic  acid  (PGA),  polylactic  acid  (PLA), 
polytetrafluoroethylene (PTFE),  ceramic and alloys.  They feature a  satisfactory 
three-dimensional  architecture  but  questionable  biocompatibility;  furthermore, 
most of the synthetic biomaterials have a poor content of information and signals 
for  the  cells.  Finally,  semi-synthetic  biomaterials  derive  from alterations  of  the 
natural  biomaterials  for  the  purpose  of  improving  their  performance.  Some 
examples are modified hyaluronic acid and hydroxyapatite derivatives.
On the basis of their application, biomaterials can be divided into supports for the 
34
reconstruction of soft tissue or for the reconstruction of hard tissue [Bressan et al. 
2011] [Gardin et al. 2011].
Soft Tissue
At present, the strategies for the reconstruction of soft tissue are based on grafts 
of autologous tissue or on bioengineered implants made up of cells inoculated in 
biocompatible supports. To this purpose, different natural biomaterials are used, 
also in association with synthetic or organic materials.
Some examples of biomaterials used in soft tissue regeneration are:
- Collagen: it is the main component of the extracellular matrix of the con-
nective tissue.  Thanks to its biocompatibility,  strength and flexibility,  it  is 
widely used to generate dermal substitutes. Several scaffolds based on col-
lagen are currently marketed as dermal substitutes, in particular in the form 
of hydrogel. These substitutes are usually obtained through the suspension 
of dermal fibroblasts in a collagen hydrogel. However, their use as a per-
manent graft is limited due to their low resistance to degradation, especially 
if the hydrogel is a low-concentration hydrogel [Helary et al. 2011]. Dermal 
substitutes made up of a collagen layer associated with dermal glycosa-
minoglycans superimposed to a silicone layer are available on the market. 
These substitutes were successfully used in the treatment of chronic cu-
taneous wounds [Kahn et al. 2011].
- Gelatin: it is produced from the hydrolysis of collagen, it has high haemo-
static power and does not cause antigenicity. Thanks to its properties, gelat-
in was widely used as a tissue adhesive for the closure of wounds [Dhan-
dayuthapani et al. 2010].
- Fibrin: it derives from the polymerization of fibrinogen in the presence of 
thrombin. It is not part of the extracellular matrix but is temporarily present 
during the healing of wounds as it is involved in blood clotting. In the field of 
regenerative medicine, fibrin glue was widely used as a tissue adhesive. 
Fibrin glue is marketed in the form of two separate solutions: one of fibrino-
gen and the other of thrombin, applicable by means of a double syringe or a 
spray. When they are mixed together, they mime the last phases of the clot-
ting cascade and form a fibrin clot [Thompson et al. 1988]. Fibrin glue was 
used, as an alternative to clips, in burn patients subjected to the removal of 
the wound and to skin graft. It has proven to be safe and efficient, giving 
better results than clipping. Furthermore, the use of fibrin glue has obtained 
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compliance from patients, since the removal of clips is often painful and re-
quires more time [Foster et al. 2008].
- Hyaluronic acid: it is a polysaccharide of the extracellular matrix diffused in 
a ubiquitous way. In an aqueous environment, it generates viscous matrices 
guaranteeing tissue hydration, it regulates the organization of matrix pro-
teoglycans, and it is also involved in cellular adhesion, proliferation, migra-
tion and differentiation.  In  vitro and  in  vivo studies  have widely  demon-
strated its potentials in the construction of three-dimensional supports use-
ful for tissue engineering [Solchaga et al. 1999] . Hyaluronic acid derivatives 
are available on the market, such as HYAFF® 11 (Fidia, Italy), a linear deriv-
ative of hyaluronic acid modified by complete esterification of the carboxyl 
groups of glucuronic acid with benzyl groups. This modification determines 
lower hydrophilicity and degradation by the hyaluronidases. The esterified 
derivatives maintain the same biological characteristics as hyaluronic acid, 
but they have a longer permanence time when they are implanted and they 
can be processed by means of various weaving techniques producing vari-
ous articles like gauzes, sponges, microspheres, granules, membranes and 
non-woven felts, with characteristics that can be adapted to many clinical 
applications [Rastrelli et al. 1990].
- Laminin: it is a glycoprotein of the extracellular matrix generally present in 
the basement membrane. It promotes cellular adhesion, migration, growth 
and differentiation. In the field of tissue engineering laminin is used to im-
prove the functionalities of  three-dimensional  supports  and to prevent  or 
minimize transplant  rejection.  It  has  been demonstrated that  associating 
laminin with a chitin-based support (a structural element of the exoskeleton 
of crustaceans) promotes the healing of wounds by fastening re-epithelializ-
ation through the reduction of inflammatory infiltrates and the higher prolif-
eration of fibroblasts [Min et al. 2010].
Hard Tissue
In general, by speaking of hard tissue reconstruction one means the regeneration 
of the hard tissue par excellence: bone tissue. At present, progresses in the field of 
nanotechnologies have allowed to produce bone substitutes alternative to bone 
tissue grafts deriving from the same patient (autotransplantation) or from donors 
(allotransplantation). Today autotransplantation is still the “gold standard” in bone 
reconstruction as it features some important qualities:
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- Osteoconductivity: ensuring cellular adhesion and proliferation in a structure 
that allows for cellular migration and for the formation of new vessels;
- Osteogenicity: ensuring the presence of osteoblasts in the graft adhesion 
seat to favour the generation of new bone tissue;
- Osteoinductivity: capability to stimulate the surrounding stem or osteopro-
genitor cells to differentiate in osteoblasts.
Despite  these  characteristics,  autotransplantation  is  associated  with  several 
collateral  effects,  among  which:  post-surgery  pain,  formation  of  hematomas, 
haemorrhages,  nervous  lesions,  infections  and  aesthetic  defects. 
Allotransplantation, on the other hand, implies a high risk of disease transmission 
and immune responses; for this reason, bone grafts, before being implanted, are 
frozen or freeze-dried. An alternative to allotransplantation is the  demineralized 
bone matrix,  produced from decalcified cortical  bone treated with radiation and 
chemical agents. The result, a bone matrix made up of denatured proteins only, is 
not  a  stable structure but  an osteoconductive substrate to  be used in case of 
structurally  stable  bone  lesions.  Although  there  exist  different  forms  of  bone 
transplantation,  they  all  share  reduced  osteoinductivity  and  the  absence  of  a 
cellular component, as the donor grafts are devitalized through radiation or freeze-
drying [Finkemeier 2002].
A way of getting round the drawbacks related to bone tissue transplantation is to 
treat the bone defects with bioengineered substitutes. In addition to the already 
mentioned characteristics of osteoconductivity, osteogenicity and osteoinductivity, 
the ideal bone substitute must possess other precise characteristics [Gardin et al. 
2012b]:
- Osseointegration: the capability to establish connections with the original 
bone tissue;
- Biodegradability;
- Morphology similar to the human bone;
- Easy clinical use;
- Economical.
A great number of bone substitutes, of natural and synthetic origin, which promote 
the proliferation, differentiation and migration of cells, are available on the market. 
Among these there are biomaterials made up of:
- Metals:  they  were  widely  used,  especially  titanium,  as  bone  substitutes 
thanks to their mechanical strength. However, after 10-15 years metal im-
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plants must be replaced due to their poor or incomplete osseointegration 
with the surrounding bone. In order to improve osseointegration, metal im-
plants were developed with nanostructured surfaces that increase their sur-
face wrinkledness and wettability favouring the absorption of proteins, cellu-
lar  adhesion and proliferation and calcium deposition  [Tran and Webster 
2009].
- Ceramics: based on calcium phosphate, such as hydroxyapatite (HA) and 
β-tricalcium phosphate (TCP), they are widely used in bone tissue regener-
ation thanks to their high biocompatibility with cells and bone tissue. Ceram-
ics are also bioactive, that is to say, they are able to support cellular adhe-
sion, proliferation and differentiation. Although HA and TCP resemble the in-
organic components of the bone matrix, their use is limited by their fragility 
and low resistance to pressure. Moreover, like metals, ceramics too feature 
a poor osseointegration, which can be made up for through the develop-
ment of nanoscale surfaces. With respect to conventional ceramics, nano-
scale ceramics feature a greater cellular adhesion and proliferation and cal-
cium  deposition  thanks  to  the  greater  wettability  and  adsorption  of  vit-
ronectin, one of the proteins involved in cellular adhesion  [Webster et al. 
2001].
- Polymers: of natural or synthetic origin. Natural polymers include polysac-
charides (alginate, chitin/chitosan, hyaluronic acid and derivatives) and pro-
teins (collagen, fibrin and silk). The advantage of natural polymers lies in 
their high biocompatibility, but synthetic polymers have no immunogenicity 
and can be processed to obtain particular characteristics  [Balasundaram 
and Webster 2007]. The most used synthetic polymers are polylactic acid 
(PLA), polyglycolic acid (PGA), and their co-polymer, polylactic-co-glycolic 
acid (PLGA). The osseointegration of polymers,  too, can be increased if 
modified on a nanoscale level, for example, through the bond with proteins 
or peptides that can increase cellular adhesion. Since the biological activity 
of the adhesion proteins is expressed through peculiar RGD sequences (ar-
ginin-glycin-aspartat), the functionalization of synthetic polymers with such 
sequences increases their interaction with integrins, the membrane recept-
ors of the RGD sequences, favouring cellular adhesion [Paletta et al. 2009].
Since the bone substitutes made up of one component only do not have all the 
characteristics of an ideal substitute, research in recent years has been focussing 
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on the combination of the above-listed materials.
Cell therapy applications for craniofacial regeneration
Interest about novel stem cell based therapies has exponentially been increasing 
over the past years, not only in the scientific community but also within the society.  
Indeed, stem cells seem to give the best chance for human tissue engineering, 
and  particularly,  mesenchymal  stem  cells  (MSCs)  represent  a  great  tool  in 
regenerative  medicine  because  of  their  ability  to  differentiate  into  a  variety  of 
specialized cells in addition to their immune privileged characteristics 
Hovewer both somatic and stem cells can be used in cell based therapy (Table 1). 
Somatic  cells  can  be  harvested,  cultured  and  implanted  with  the  aim  of 
engineering new tissues. Limitations in their use are related to the lack of self-
renewal capability and limited potency; characteristics that are exclusive of stem 
cells [Garcia-Godoy and Murray 2006]. Somatic cell delivery and stem cell therapy 
cells have been evaluated in different areas of regenerative medicine.
Somatic  cells  in  the  craniofacial  region,  fibroblast-like  cells  derived  from  the 
periodontal ligament have been used to promote periodontal regeneration [Dogan 
et al.  2002; Dogan et al.  2003]. As demonstrated through in vivo investigations 
using  a  labeling  technique,  oral-derived periodontal  cells  are  able  to  stimulate 
alveolar  bone formation  [Lekic  et  al.  2001].  Cloned tooth-lining  cementoblasts, 
periodontal  ligament  fibroblasts,  and  dental  follicle  cells  seeded  onto  three-
dimensional polylactic-co-glycolic acid scaffolds, exhibit mineral formation in vitro 
[Jin  et  al.  2003b].  Immortalized  cementoblasts  delivered  to  large  periodontal 
defects via biodegradable PLGA polymer sponges contributed to complete bone 
bridging  and PDL formation,  while  dental  follicle  cells  inhibited bone formation 
[Zhao et al. 2004].
Another  study  showed  that  skin  fibroblasts  transduced  by  the  BMP-  7  gene 
promoted the regeneration of periodontal defects including new bone, functional 
PDL and tooth root cementum [Jin et al. 2003a]. In the management of soft tissue 
defects cultivated fibroblasts have also been used for the treatment of interdental 
papillary  insufficiency  [McGuire  and  Scheyer  2007].  A  human  oral  mucosa 
equivalent,  made  of  autogenous  keratinocytes  on  a  cadaveric  dermal  carrier 
(Alloderm®) was able to favor wound healing when compared to the dermal carrier 
alone  [Izumi  et  al.  2003].  An  ex  vivo  synthesized  oral  mucosa  equivalent 
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(EVPOME)  produced without  using  animal-derived serum or  feeder  layer  cells 
[Hotta et al. 2007; Song et al. 2004] has demonstrated its ability to promote early 
initiation of epithelialization, short healing period and minimal scar contraction.
This can be partially  explained by the ability  of  this  living construct  to  secrete 
growth  factors  as  VEGF,  promoting  initial  vascularization,  which  is  critical  to 
subsequent graft survival  [Nakanishi et al. 2007; Xu et al. 2009]. EVPOME has 
been successfully used to treat patients affected by squamous cell carcinoma of 
the tongue, leukoplakia of the tongue, gingiva, and buccal mucosa or hypoplasia 
of the alveolar ridge [Hotta et al. 2007]. In other soft tissue applications, allogenic 
foreskin fibroblasts have been utilized to promote keratinized tissue formation at 
mucogingival defects [McGuire and Nunn 2005]. A tissue-engineered living cellular 
construct  comprised  of  viable  neonatal  keratinocytes  and  fibroblasts  rendered 
similar  clinical  outcomes  when  compared  to  conventional  gingival  autografts 
[McGuire  et  al.  2011].  This  construct  has a  strong potential  to  promote  tissue 
neogenesis  through  the  stimulation  of  angiogenic  signals  [Morelli  et  al.  2011]. 
Another interesting product consists of the application of neonatal keratinocytes 
and  fibroblasts  for  increasing  keratinized  gingiva  around  teeth  [McGuire  et  al. 
2008]
This cell construct can stimulate the expression of angiogenic-related biomarkers 
as  compared  with  autogenous  free  gingival  grafts  during  early  wound-healing 
stages  [Morelli  et  al.  2011] and,  therefore,  constitutes  a promising material  for 
gingival grafting without the need of a donor site.
The benefits of using somatic cells for the regeneration of soft and hard tissues in 
the  craniofacial  district  have  been illustrated  by  several  preclinical  and  clinical 
studies  [Mao et al.  2006].  Although, the lack of selfrenewal capability and their 
commitment toward a single cellular. Phenotype limit their use in the treatment of 
more  challenging  craniofacial  defects,  in  which  a  more  orchestrated  cellular 
response may be critical to gain success. Given their higher characteristics, stem 
cells might have a greater potential in this area.
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Table 1: Cell therapy applications for periodontal/craniofacial tissue engineering.
Regenerative cell construct Study model References
Autologous 
Stem Cells
Bone block allografts impregnated with autogenous bone marrow Patients with severely atrophic maxillary and mandibular ridges [Soltan et al. 2007]
Autologous MSCs isolated from a bone marrow aspirate and expanded in vitro Periodontal regeneration in class III furcations in a dog model [Kawaguchi et al. 2004]
Engineered porous scaffold seeded with BMSCs Postextraction socket in rabbits [Marei et al. 2005]
PRP+MNCs from bone marrow aspirate Alveolar ridge augmentation in humans [Filho Cerruti et al. 2007]
PRP + in vitro-expanded bone marrow derived MSCs Trephined defects in dog mandibles [Yamada et al. 2004c; Yamada et 
al. 2004b; Yamada et al. 2004a]
PRP+in vitro-expanded bone marrow derived MSCs Periodontal defects in humans [Yamada et al. 2006]
Adipose-derived stem cells Periodontal defects in Wistar rats [Tobita et al. 2008]
BMSCs incorporated with a PLCL scaffold Osteochondral defect on the medial femoral condyles at a high load- bearing 
site on a rabbit's knee joint
[Xie et al. 2010]
NELL-1 modified autogenous BMSCs in PLGA scaffold Surgically-created osteochondral defects in goats' mandibular condyles [Zhu et al. 2011]
Autologous periodontal ligament cells from extracted teeth in a hyaluronic acid carrier Dehiscence defects in beagle dogs [Akizuki et al. 2005]
PDL stem cells from extracted teeth Surgically-created periodontal defects in miniature pigs [Liu et al. 2008]
mp2-supplemented dental pulp stem cells On amputated pulp to stimulate reparative dentin formation [Iohara et al. 2006]
BMSCs cryopreserved for 1 month and freshly isolated BMSCs (control) Periodontal fenestration on beagle dogs [Li et al. 2009]
Allogenic So­
matic Cells
Fibroblast-like cells from expanded regenerated periodontal ligament cells Artificial class II furcal defect in a dog model [Dogan et al. 2002; Dogan et al. 
2003] 
Periodontal ligament cells Periodontal defects created in Sprague–Dawley male rats [Lekic et al. 2001]
Cultured cementoblasts, periodontal ligament fibroblasts, and dental follicle cells Ectopic tissue regeneration in mice using 3-D poly lactic-co-glycolic acid 
(PLGA) scaffolds
[Jin et al. 2003b]
Cultured primary follicle cells and immortalized cementoblasts Buccal periodontal defects in mandibular molar of athymic rats [Zhao et al. 2004]
Syngeneic skin fibroblasts transduced by the BMP-7 gene Periodontal ligament regeneration at sites with periodontal bone defects in 
rats
[Jin et al. 2003b]
Living human fibroblast-derived dermal substitute (Allogenic foreskin fibroblasts and 
keratinocytes)
Patients with insufficient attached gingiv [McGuire and Nunn 2005]
Living human fibroblast-derived dermal substitute (Allogenic foreskin fibroblasts and 
keratinocytes)
Multi center study treating patients with insufficient attached gingiva but no 
need for root coverage
[McGuire and Scheyer 2007]
Autologous 
Somatic Cells
Periodontal ligament cell sheets with reinforced hyaluronic acid carrier Surgically create dehiscence defects [Akizuki et al. 2005]
Cultured and expanded autologous fibroblasts Injections for papilla priming procedure to augment open interproximal spa-
ces
[McGuire and Scheyer 2007]
Ex vivo produced oral mucosa equivalent (EVPOME, Autogenous keratinocytes seeded 
on Alloderm®)
Patients with either a premalignant or cancerous mucosal oral lesion [Izumi et al. 2003]
Ex vivo produced oral mucosa equivalent (EVPOME, Autogenous keratinocytes seeded 
on Alloderm®
Patients affected by squamous cell carcinoma of the tongue, leukoplakia of 
the tongue, gingiva, and buccal mucosa or hypoplasia in the alveolar ridge
[Hotta et al. 2007]
Autogenous chondrocytes expanded in presence of FGF-2 and TGFß1 Cartilage defects in the knee [Brittberg et al. 1994; Jakob et al. 
2001; Dozin et al. 2005; Dozin et 
al. 2002]
Engineered cartilage generated in vitro from chondrocytes cultured on a biodegrada-
ble scaffold
Osteochondral defect in a rabbit knee joint [Schaefer et al. 2002]
PDL-derived cells cultured and placed on the surface of Ti pins Implantation on nude mice, beagle dogs and human patients [Gault et al. 2010]
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Stem cells 
Stem cells  are  cells  which  can  continuously  divide  generating  undifferentiated 
(self-renewing)  or  specialized (multilineage  differentiation)  daughter  cells.  They 
can divide symmetrically, to increase the number of stem cells, or asymmetrically 
to keep the number of stem cells unvaried and generate parent cells, which in turn 
will differentiate into mature cells. [Bluteau et al. 2008].
Commonly stem cells are grouped in Embryonic Stem Cells (ESC) and Adult Stem 
Cells (ASC).
ESC are derived from inner cell mass of a  blastocyst of an early-stage embryo. 
They are named pluripotent stem cells since they are able to differentaiate into all 
types of cells of an adult individuum.
On the contrary ASC are simply multipotent  as their  differentiation potential  is 
limited to specific cell lines.
ASC reside in different organs and tissues in microenvironments named “stem cell 
niches” consisting of heterogeneous cells, extracellular matrix and soluble factors 
which support the maintenance and self-renewal of stem cells.  [Yen and Sharpe 
2007]
For this reason ASC are also named postnatal or somatic cells. ASC cannot be 
identified with certainty but only on the basis of indirect properties such as the 
expression of a specific range of surface markers, slow cell cycle, clonogenicity 
and undifferentiated state.
The best way to determine staminality is the  self-renewal assessment based on 
the isolation of likely-to-be stem cells and their subsequent transplant in order to 
evaluate their ability to reconstruct host tissue [Bluteau et al. 2008].
Mesenchymal stem cells (MSC) are non-hematopoietic cells of mesodermal and 
neuroectodermal origin. They can be found in many soft tissues (Table 2) such as 
bone marrow, adipose tissue, umbilical cord and dental pulp. They differentiate to 
form mesoderm derived cells  e.g.  adipocytes,  chondrocites and osteocytes but 
also cells belonging to the others germ layers (Table 3). As a matter of fact, it is 
known  that  MSC  have  a  higher  plasticity  degree  in  respect  to  other  ASC 
populations and are able to differentiate in vitro to form non-mesodermal cell lines 
such as neurons and astrocytes.
It appears that their function in the human body is to grant a supply of repairing 
cells without distinctive characteristics but receptive to signals which can guide 
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them to  generate  different  specialized  cell  lines.  The  destiny  of  MSC can  be 
influenced  by  signals  of  different  nature:  by  tissue  damages  such  as  trauma, 
fracture, inflammation, necrosis and tumor, by chemotactic signals and by signals 
coming from the surrounding micro environment. [Pountos and Giannoudis 2005].
Besides multipotency, MSC possess further important qualities: they can be easily 
amplified in a laboratory using standard cultivating conditions and the source they 
are derived from is not encountering ethical problems.
Table  2 List  of  tissues  where  MSC have  been found and 
related references.
Source Reference
Bone marrow stroma Jones E. A., 2002
Adipose tissue Zuk P. A., 2001
Trabecular bone Tuli R., 2003
Joint cartilage Alsalameh S., 2004
Synovial membrane De Bari C., 2003
Muscle Young H. E., 2001
Tendon Salingcarnboriboon R.,2003
Umbilical cord Romanov Y. A., 2003
Blood vessels Abedin M., 2004
Blood Kuznetsov S. A., 2001
Skin Toma J. G., 2005
Dental pulp Gronthos S., 2000
Foetal tissues Muench M. O., 2002
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Table  3: List  of  cell  lines  generated  by  MSC and  related 
references.
Differentiation Reference
Osteoblasts Jones E. A., 2002
Chondrocytes Jones E. A., 2002
Adipocytes Jones E. A., 2002
Cardiomyocytes Orlic D., 2001
Fibroblasts Ogawa M., 2006
Myofibroblasts Ogawa M., 2006
Skeletal muscle De Bari C., 2003
Tenocytesi Pittenger M., 2002
Neurons Long X., 2005
Astrocytes Mimura T., 2004
Hepatocytes Lee K. D., 2004
Pancreatic cells Chen L. B., 2004
Their high ability to proliferate together with their multipotency and their elevated 
differentiation potential make MSC interesting candidates for tissue regeneration.
MSC have been discovered and first characterized in the bone marrow stroma and 
named bone marrow-derived mesenchymal stem cells (BMMSC) [Friedenstein et 
al. 1970]. They can be easily obtained, considerably amplified in vitro and utilized 
in cell-mediated therapy and tissue engineering.
However, clinical use of BMMSC is limited by a range of problems among which 
painful sample taking, often combined with a low number of cells per sample. For 
this reason, a number of researchers have begun to look for more accessible and 
abundant alternative sources from where MSC can be obtained with less invasive 
sample-collection procedures.
Adipose tissue-derived stem cells
Adipose  tissue,  just  like  bone  marrow,  derives  from  mesenchyme  and  is 
characterized by an easy-to-isolate supportive stroma. Adipose tissue could easily 
represent an alternative source to bone marrow when isolating stem cells. Through 
liposuction operations it is possible to collect a large amount of adipose derived 
stem cells (ADSC) which can be effortlessly amplified in vitro. In fact, in standard 
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cultivating conditions and without special caution, ADSC grow rapidly showing a 
stable proliferation kinetics [Zuk et al. 2001].
It has been demonstrated that ADSC, just like BMMSC, can differentiate  in vitro 
into osteocytes, adipocytes, myocytes and chondrocytes, if treated with specific 
differentiation  factors.  Such  a  plasticity  further  confirms  that  adipose  tissue  is 
composed of a population of multipotent stem cells whose ability to differentiate 
equals BMMSC.
ADSC staminality has been confirmed by the characterization of CD (cluster of 
differentiation) antigen markers. Analogously to BMMSC, ADSC express markers 
on the cell surface: CD29, CD44, CD71, CD90, CD105/SH2 e SH3, which together 
with SH2, is considered a marker for MSC [Haynesworth et al. 1992].
Besides  these  markers,  ADSC and  BMMSC alike  express  STRO-1,  a  marker 
utilized to isolate bone marrow mother cells [Dennis et al. 2002]. On the contrary 
ADSC do not  express the markers  of  the hemopoietic  lineage CD31,  CD34 e 
CD45. In addition they are positive for CD13 but negative for CD14, CD16, CD56, 
CD61, CD62E, CD104 e CD106. ADSC differ from BMMSC just for the expression 
of two antigen markers: CD49d and CD106. In particular, ADSC express CD49d 
but not CD106, whereas the converse has been observed in BMMSC [Zuk et al. 
2002].  The  expression  of  CD106  is  functionally  associated  to  hematopoiesis 
[Lévesque et al. 2001], consequently the lack of expression of this antigen marker 
in ADSC is coherent with their localization in a non-haematopoietic tissue.
Since adipose tissue - just like bone marrow stroma - derives from mesoderm, it is 
non unlikely to observe ADSC differentiation into cells of the mesodermal lineage. 
However,  their  differentiation into  cells  of  the neuronal  phenotype -  generating 
cells with similar morphology and expression of protein markers similar to nervous 
cells - has likewise been documented [Franco Lambert et al. 2009].
It  is  concluded  that  ADSC  possess  all  the  characteristcs  typical  of  MSC: 
fibroblastoid  morphology,  ability  to  form  single  colonies  named  CFU-F 
(fibroblastoid colony-forming units),  expression of the typical set of cell  surface 
markers, multipotency as well as ability to differentiate into cells of the mesodermal 
lineage [Kern et al. 2006].
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Dental pulp stem cells
Dental pulp is a soft connective tissue of mesenchymal origin trapped inside the 
pulp  cavity  of  the  tooth.  It  is  possible  to  identify  four  layers  in  the  pulp:  the 
outermost layer composed of odontoblasts which generate dentine; a second layer 
called “cell free zone”, poor in cells but rich in collagen fibers; a third layer called 
“cell  rich  zone” containing  progenitor  cells  and  undifferentiated  cells,  some of 
which  are  stem  cells;  an  innermost  layer,  located  in  the  center  of  the  pulp 
chamber, rich in both vessels and nerve networks. Stem cells and undifferentiated 
cells contained in the “cell rich zone” can migrate to variuous district where - driven 
by different stimuli – can originate new differentiated cells and specialized tissues 
[d'Aquino et al.  2007]. Dental pulp of the third molar, although often discarded, 
represents an easily accessible source of MSC.  It was only in the year 2000 that 
dental pulp stem cells  (DPSC) were first identified and isolated according to their 
clonogenic abilities and their high proliferation speed. [Gronthos et al. 2000]. Later, 
more than four types of MSC cells derived from dental pulp have been identified: 
stem cells  from human exfoliated deciduous teeth (SHED)  [Miura et  al.  2003], 
stem cells  derived from periodontal  ligaments (PDLSC)  [Seo et al.  2004] stem 
cells from the apical papilla (SCAP)  [Sonoyama et al.  2006] and dental  follicle 
progenitor cells (DFPC) [Morsczeck et al. 2005]. They all show multipotency and 
ability to regenerate different dental and periodontal tissues  in vitro and  in vivo 
[Huang 2009].
In addition,  they are positive for markers STRO-1, CD13, CD24, CD29, CD44, 
CD73, CD90, CD105, CD106, CD146, Oct4, Nanog e β2 integrin, but negative for 
CD14,  CD34,  CD45  e  HLA-DR.  The  persistence  of  negativity  for  CD45  and 
positivity for CD34 demonstrates that DPSC are not derived from a hematopoietic 
source, but are of mesenchymal origin  [d'Aquino et al. 2007]. Just like all MSC, 
DPSC are a heterogeneous population and the different markers listed above can 
be expressed in subpopulations of the same cells [Huang 2009].
They  can  survive  in  culture  for  long  periods  and  be  maintained  for  several 
passages: clear signs of senescence have not been detected up to 80 passages. 
Furthermore,  they  can  be  cryopreserved  for  long  periods  without  losing  their 
multipotency [Laino et al. 2005].
It has been demonstrated their differentiation into odontoblasts, the cells producing 
the mineralized matrix of dentine [Gronthos et al. 2000]. However, DPSC can also 
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differentiate into adipocytes and neurons showing both morphology and respective 
markers. In addition, their chondrogenic and myogenic differentiation  in vitro has 
been observed. DPSC plasticity and multipotency can be related to the origins of 
dental pulp, consisiting both of ectodermic and mesodermic components and of 
neural crest derived cells. [d'Aquino et al. 2009].
Scaffolds for cell therapy delivery to oral and craniofacial  
defects
As  underline  previously,  Scaffolds  play  a  pivotal  role  in  providing  a  three-
dimensional template for tissue neogenesis [Ma 2008]. Scaffolds can not only be 
used as carriers for cell  delivery but also serve as synthetic extracellularmatrix 
environments  to  define a 3D geometry  for  tissue regeneration and provide an 
adequate microenvironment in term of chemical  composition,  physical  structure 
and biologically functional moieties [Rice et al. 2005; Liu and Ma 2004].
Thus far, the most widely adopted scaffolds for craniofacial bone regeneration are 
xenogenic and allogenic  bone substitutes,  hydroxyapatite,  calcium phosphates, 
and gelatin or collagenous sponges  [Kawaguchi et  al.  2004; Lekic et al.  2001; 
Nakahara et al. 2004; Kaigler et al. 2010a; Kaigler et al. 2010b]. Limitations in their 
use  are  related  to  the  lack  of  degradability  of  certain  materials  or  too  fast  
degradability  of  others,  poor  processability  into  porous  structures,  brittleness, 
inability to generate structures to be tailored to the specific needs of the patient or 
inability  to  maintain  the  desired  volume  under  mechanical  stimuli.  In  order  to 
overcome these limitations synthetic scaffolds specifically designed to mimic the 
wound healing extracellular matrix are being evaluated.
This  biomimetic  concept  applied  to  materials  synthesis  intends  to  generate 
biodegradable scaffolds with a highly porous structure and adequate mechanical 
properties for bone engineering  [Ma 2008]. Ideally, a scaffold material should be 
degradable  at  a  rate  similar  to  that  of  the  new  tissue  formation,  large 
interconnected pores are required to allow for cell  incorporation, migration, and 
proliferation  [Zhang  and  Ma  2000].  Bone  formation  occurs  over  a  structured 
collagen matrix with fiber bundle diameter varying from 50 to 500 nm [Hay 1991; 
Elsdale and Bard 1972], therefore nanofibrous scaffolds appear to provide better 
cellular attachment [Woo et al. 2003], increased differentiation of osteoblastic cells 
[Chen et  al.  2006],  and enhanced mineral  deposition compared to  solid-walled 
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scaffolds [Woo et al. 2007].
Electrospinning, self-assembly, and phase separation are three different methods 
employed  in  the  fabrication  of  nano-fibrous  polymeric  scaffolds  for  tissue 
engineering. Electrospinning is a simple method, which utilizes an electric field to 
draw a polymer solution from an orifice to a collector, producing polymer fibers 
[Dosunmu  et  al.  2006;  Jia  et  al.  2002].  It  can  be  used  to  produce  thin  two-
dimensional  sheets,  while  three-dimensional  nanofibrous  scaffolds  have  been 
fabricated by layering these 2D sheets  [Matthews et al.  2002] or by combining 
electrospinning with 3D printing [Moroni et al. 2008]. Molecular self-assembly uses 
non-covalent  bonds  such  as  hydrogen  bonds,  van  der  Waals  interactions, 
electrostatic  interactions,  and  hydrophobic  interactions  for  fabricating 
supramolecular architectures  [Whitesides et al.  1991].  Limitations in the use of 
self-assembly methods are related to difficulties in forming macropores and limited 
mechanical  properties  [Smith  et  al.  2009].  Finally,  thermally  induced  phase 
separation (TIPS) technique can be used to fabricate nano-fibers through polymer 
dissolution,  phase  separation  and  gelation,  solvent  extraction,  freezing,  and 
freeze-drying under vacuum  [Ma and Zhang 1999]. This technique can also be 
combined with processing techniques such as particulate leaching or 3D printing 
to design complex 3D structures with well-defined pore morphologies [Chen et al. 
2006; He et al. 2010; Wei and Ma 2006].
Another interesting aspect of polymer scaffolds is that CAD/CAM technologies can 
be  applied  to  create  patient-specific,  anatomically  shaped  scaffolds.  As 
craniofacial defects and anatomical structures may greatly vary among different 
individuals a scaffold unique to each patient can be helpful in regenerating defects 
with complex geometry [Ma 2008].
Polymers have great design flexibility and their composition and structure can be 
designed to match the specific needs of the tissue to be engineered. Moreover, 
benefits can be reached by adding nano-crystalline hydroxyapatite to the scaffolds 
as  it  has  a  strong  potential  for  attracting  osteoblasts  (osteoconductivity),  it 
improves its mechanical properties [Wei and Ma 2004], and may reduce adverse 
effects associated with the degradation of some synthetic polymers  [Smith et al. 
2009]. Hydroxyapatite crystals can be incorporated during processing of polymer 
scaffolds  or  they  could  be  biomimetically  grown  onto  a  prefabricated  polymer 
scaffold.  Since  all  interactions  with  biological  components  occur  at  the  pore 
surface, the non-exposed ceramic is in effect wasted [Smith et al. 2009] and could 
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affect biodegradability and mechanical  properties of the scaffold.  It  is  therefore 
recommended to allow apatite to form as a coating of the polymer scaffold in order 
to enhance its surface characteristics.
An  interesting  technology  has  been  described  in  which  prefabricated  polymer 
scaffold are soaked in simulated body fluid in order to allow apatite crystals to 
grow onto its pore surfaces [Boskey 2003; Boskey 1998].
Growth factors can easily be incorporated in polymeric scaffolds  [Elisseeff et al. 
2001; Wei et al. 2007; Jin et al. 2008], which would allow for a more sustained 
release of  the molecules and better  properly  orchestrated tissue formation.  As 
such,  3D porous, nanofibrous scaffolds have supported various stem cells and 
differentiated cells to regenerate many hard and soft tissues.
It  should  be  pointed  out  that  significant  technical  challenges  remain  for  the 
synergistic  integration  of  structural  cues  with  biological  cues  for  cell-based 
therapies to achieve functional dental and craniofacial tissue regeneration [Gupte 
and Ma 2012]. However, it is likely that the continuous expansion of biomimetic 
approaches in the scaffolding materials design will substantially advance the field 
of  tissue  engineering  and  regenerative  medicine.  Recently,  a  biomimetic  fiber-
guiding scaffold using solid free-form fabrication methods that custom fit complex 
anatomical defects to guide functionally-oriented ligamentous fibers in periodontal 
regeneration has been successfully tested in vivo  [Park et al. 2012] and work is 
being done to incorporate biomimetic scaffolds in cellular delivery for craniofacial 
bone regeneration in many other clinical scenarios 
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Aim
The  percentages  related  to  total  edentulism  and  to  the  connected  social 
consequences represent an important problem.
Dental implant tooth replacements, one of the most popular therapies for total or 
partial edentulism, however not always is a possible solution.
Extremely atrofy or bone loss need to reconstruction before inserting implant.
Autogenous tissues have been widely used and are still considered as the gold 
standard to which all other biomaterials are compared.
Nevertheless,  even the most  advanced reconstructive techniques using autolo-
gous materials are often insufficient to restore extensive or complex maxillofacial 
defects.
However, the use of autogenous tissue involves the need of harvesting it  from
a donor site, with the consequent drawbacks in terms of costs, procedure time, pa-
tient discomfort and possible complications.
Otherwise implant may be affected by a similar condition of periodontics known as 
periimplantitis.
The latter can cause severe destruction of the peri-implant hard and soft tissues.
The Aims of this thesis are:
1. To evaluate whether the tissue engineering, through the use of stem cells, 
can be an effective therapy for the alveolar bone regeneration.
For this first purpose, we wanted to test :
a) the properties and safety of stem cells taken from different postnatal 
tissues;
b) the ability of stem cells to promote bone regeneration both in vitro 
and on small and large size animal.
 
2. Use the tissue engineering in the area of bone inflammation both in the 
therapeutic environment and in prevention, and more specifically to:
a) test stem cells anti inflammatory capability;
b) try  to  identify  a  genetic  predisposition  in  the  peri-implantitis 
development.
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Materials and methods
In Vitro
To  test  the  properties  and  safety  of  stem  cells  taken  from different  postnatal 
tissues we have used those materials and methods with experimental in vitro.
Isolation and culture of adult stem cells
Adult stem cells from adipose tissue (ADSCs)
Adipose-derived stem cells (ADSCs) were isolated from samples of subcutaneous 
adipose tissue of patients subjected to abdominoplasty, upon informed consent. 
[Gardin et al. 2012a]
Abdominal  fat,  washed in  PBS and broken into  small  pieces,  was digested in 
agitation for 3 hours at room temperature. Digestion was carried out with a 0.075% 
solution of  Collagenase from Clostridium histolyticum type II (Sigma) in  Hank’s 
Balanced Salts  Solution (HBSS, Lonza).  The enzymatic  activity  of  collagenase 
was blocked with an equal volume of complete Dulbecco's Modified Eagle Medium 
(DMEM, Lonza), made up of DMEM, 10% Fetal Bovine Serum (FBS, Gibco) and 
1% Penicillin/Streptomycin (P/S, Lonza). The cells, collected by centrifugation at 
1200 revolutions per minute (rpm) for 4 minutes, were washed in PBS and filtered 
through a 70 m strainer (BD Biosciences) to eliminate the residues of digestion. 
Finally, the collected cells were inoculated in F75 flasks (BD Falcon) with complete 
DMEM low glucose (Lonza) and placed in a humidified incubator with 5% CO2 and 
at 37°C.
Two days after digestion, the non-adherent cells (mature adipocytes and red blood 
cells) and the culture medium were eliminated and replaced with fresh complete 
DMEM low glucose. Afterwards, the culture medium was changed every 2 days.
Adult stem cells from dental pulp (DPSCs)
The dental pulp was extracted from healthy third molars of adults, upon informed 
consent. Donors of both genders, non-smokers, not subjected to pharmacological 
therapy and with no oral and systemic infections were chosen. The extraction of  
the third molars was preceded by a dental hygiene session.[Bressan et al. 2012]
The dental  pulp was isolated by mechanical  disruption of  the  crown within  24 
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hours from the extraction of each molar (Figure 9)
Figure 9: Sources of adult stem cells in dental tissues. (A) After a tooth was 
cut horizontally, the pulp tissue (arrow) in the pulp chamber was exposed; 
this pulp provides dental pulp stem cells (DPSCs). (B) Extracted impacted 
third molar (10-year-old female) containing the dental follicle (dotted line) that 
provides dental follicle stem cells (DFSCs). Bar: 5 mm. 
The dental pulp, broken into small pieces and washed in PBS, was digested with a 
HBSS solution  made  up of  Worthington  Collagenase type  I (3  mg/ml)  and  of 
Dispase II (Roche) (2 mg/ml) for 1 hour in a humidified incubator with 5% CO2 and 
at 37°C.
Digestion was blocked by adding an equal volume of complete DMEM. The cells, 
collected by centrifugation at 1200 rpm for 4 minutes, were inoculated in 24-well 
plates (BD Falcon) with complete DMEM and placed into a humidified incubator 
with 5% CO2 and at 37°C.
After 3 days from digestion, the residues of digestion and the non-adherent cells 
were eliminated and replaced with fresh complete DMEM. Afterwards, the culture 
medium was changed every 2 days.
Biomaterials:
The following biomaterials were used:
- Hyaluronic acid;
- Fibrin;
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- Hydroxyapatite.
A hyaluronic acid derivative was used for the in vitro reconstruction of dental-like 
tissue:  HYAFF 11® (Fidia,  Abano Terme,  PD,  Italy).  Since hyaluronic  acid  is  a 
highly  hydrophilic  linear  polymer,  in  an  aqueous  environment  it  generates  a 
viscous  gel  that  drastically  reduces  its  workability.  In  order  to  reduce  its 
hydrophilicity, keeping its biological properties unchanged, the hyaluronic acid was 
submitted to an esterification process of the carboxyl groups with benzyl alcohol.
HYAFF 11® is the 100% benzyl ester of hyaluronic acid. It is insoluble in aqueous 
solution but biodegradable, as the hydrolysis of the esteric bond determines the 
release of benzyl acid (eliminated with the urine) and of hyaluronic acid, which 
follows the same metabolic pathway as endogenous hyaluronic acid.
HYAFF 1® was used in the form of non-woven tissue with a specific weight of 
100 g/m2, made up of 20-μm-thick fibres and having a size of 1 cm2.
Two different hydroxyapatite-based biomaterials were used for vascularized bone 
tissue  reconstruction:  Orthoss® (Geistlich  Pharma AG,  Switzerland)  for  in  vitro 
experiments  and  Bio-Oss® (Geistlich  Pharma  AG,  Switzerland)  in  in  vivo 
experiments.
Orthoss is made up of carbonate-natural nanocrystalline hydroxyapatite deriving 
from the purification and sterilization of bovine bones. Therefore, it is an inorganic 
bone  matrix  with  a  microporous  and  macroporous  structure  similar  to  human 
spongy bone. In the in vitro experiments it was used in the form of blocks having a 
size of 1 cm × 1 cm × 2 cm. Bio-Oss, too, derives from the mineral component of 
bovine bone matrix, but it is in the form of granules having a size of 0.25-1 mm.
Differentiation
A culture medium containing both osteogenic differentiation factors and endothelial 
differentiation factors was used for in vitro vascularized bone tissue reconstruction.
Osteo-Endothelial Differentiation Medium:
- Endothelial Basal Medium;
- 2% FBS;
- 1% P/S;
- 10 ng/ml FGF-b;
- 10 ng/ml EGF;
- 10 mg/ml Heparin;
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- 1 mg/ml Hydrocortisone;
- 10 mM -Glycerophosphate;
- 10 nM Dexamethasone.
Finally,  in vitro dental-like tissue reconstruction was carried out by imbibing the 
biomaterial  with  a  mixture  of  neuronal  factors  in  the  presence  of  endothelial 
differentiation medium.
Mixture of Neuronal Factors: - 50 ng/ml NGF-
- 50 ng/ml BDNF;
- 10 ng/ml NT-3;
- 4 mM Forskolin;
- 10 ng/ml Heregulin 
- 40 ng/ml FGF-b;
- 20 ng/ml EGF.
Endothelial Differentiation Medium:
- Endothelial Basal Medium;
- 2% FBS;
- 1% P/S:
- 3 ng/ml FGF-b;
- 10 ng/ml EGF;
- 10 mg/ml Heparin;
- 1 mg/ml Hydrocortisone.
Proliferation tests
MTT Assay
The cell proliferation rate was assessed by MTT assay, according to the method 
by Denizot et al. [Denizot F., 1986]. It is a colorimetric assay that measures in a 
quantitative  manner  the  activity  of  the  mitochondrial  enzyme  succinate 
dehydrogenase  of  the  cells  being  cultured.  This  enzyme,  active  in  the 
mitochondria  of  viable  cells  only,  is  normally  used  as  a  marker  of  the  cells’ 
metabolic activity, viability and growth.
The assay is based on the reduction of the chemical compound MTT, that is to say, 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide,  a  yellow tetrazolium 
dye,  in  blue  formazan  salts,  by  mitochondrial  succinate  dehydrogenase.  The 
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amount  of  formazan  produced  is  proportional  to  the  activity  of  mitochondrial 
succinate dehydrogenase and,  therefore,  directly proportional to the number of 
viable cells. By means of spectrophotometric reading, at a wavelength of 570 nm, 
it is possible to quantify the formazan salts and, then, correlate the optical density 
(O.D.) value to the number of cells.
The assay was carried out by incubating for 3 hours the cell samples with 1 ml 
MTT solution - 0.5 mg/ml - in PBS in a humidified incubator with 5% CO2 and at 
37°C. Afterwards, the MTT solution was eliminated gently and the formazan salts 
were dissolved in 500 l extraction solution (90% isopropanol and 10% dimethyl 
sulfoxide) for 15 minutes at room temperature. Finally, the formazan blue solutions 
were read at the spectrophometer at a wavelength of 570 nm.
Population Doubling Time 
The assessment of the proliferative capacity of the DPSC cells included the study 
of the Population Doubling Time (PDT).
The analysis was carried out at passages p2, p5 and p8 inoculating 5 x 104 cells in 
12-well plates (BD Falcon). At intervals of 24 hours from inoculation, the number of  
adherent cells was determined for each passage by detaching them with an EDTA 
0.02% and  tripsin  0.25% solution  (Lonza)  and  counting  them with  the  Bürker 
chamber (Marienfeld Superior).
The PDT was calculated by applying the following formula:
PDT = (T – T0) × log 2 / (log Nt - log N0)
wherein (T – T0) indicates the culture time expressed in days, Nt is the average 
number of cells collected at time T, and N0 is the number of cells inoculated in 
each well/plate at time 0.
Morphological study
Immunofluorescence
Monolayer immunofluorescence analyses were carried out by culturing the cells on 
slides (having a diameter of 19 mm) pre-treated with a 2% aqueous solution of 
Gelatin B extracted from bovine skin (Sigma Aldrich) in the presence of complete 
DMEM or of differentiation medium. The analysis required the fixation of the cells 
on the slides with a 3.7% formalin solution for 15 minutes at room temperature.
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The three-dimensional constructs, on the other hand, were fixed in formalin for two 
hours and then dehydrated through ascending alcohols: the samples were soaked 
in ethyl  alcohol  solutions with growing concentration (from 50% to 100%) with 
double passages of 15 minutes each, to gradually eliminate the water content, 
before passing  through xylene until  clearing.  After  the inclusion in  paraffin  the 
samples were cut  into slices having a thickness of 6  m and submitted to the 
immunofluorescence reaction.
The samples,  after  two washes in PBS,  were treated for  one hour  with a 2% 
Bovine Serum Albumin (BSA, Sigma) solution in PBS to reduce the non-specific 
bonds of primary antibodies. Afterwards, the following primary antibodies diluted in 
BSA at 2% were incubated for one night at 4°C:
- Chicken anti Human CNPase (Millipore);
- Chicken anti Human III -tubulin (Millipore);
- Mouse anti Human CD31 (Abcam);
- Mouse anti Human Nestin (Covance);
- Mouse anti Human Vimentin (Sigma);
- Rabbit anti Human CD105 (Santa Cruz);
- Rabbit anti Human CD73 (Abcam);
- Rabbit anti Human CD90 (Abcam);
- Rabbit anti Human GFAP (Millipore);
- Rabbit anti Human S100 (Sigma);
- Rabbit anti Human von Willebrand Factor (Dako).
After  a  wash  in  PBS,  the  samples  were  incubated  for  one  hour  at  room 
temperature with the following secondary antibodies:
- Goat anti Chicken IgG (H + L) TRITC labeled (KPL);
- Goat anti Mouse IgG (H + L) FITC labeled (KPL);
- Goat anti Rabbit IgG (H + L) TRITC labeled (KPL).
Following a wash in PBS, the nuclei were marked with Hoeches 33342 (Sigma) for 
15 minutes at room temperature. After a short wash in PBS, the mounting on slide 
holders was carried out with ProLong® Gold antifade reagent (Invitrogen).
The immunofluorescence images were acquired by means of the Zeiss Axioplan 
microscope (Carl  Zeiss, Germany),  coupled with the Leica DC500 camera and 
with  the  Leica  IM1000  Image Manager  v1.20 software  (Leica,  Germany).  The 
images were acquired at 40x enlargements.
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Scanning Electron Microscopy (SEM)
The constructs, previously washed in PBS, were washed with a 2% glutaraldehyde 
solution in a 0.1 M sodium phosphate buffer with 7.2 pH and preserved at 4° C 
until the moment of dehydration. The latter, preceded by three washes in 0.1 M 
sodium  phosphate  buffer,  was  carried  out  through  ascending  alcohols:  the 
samples  were  soaked  in  solutions  of  ethyl  alcohol  with  growing  concentration 
(from 20% to 96%) with double passages of 5 minutes each, to gradually eliminate 
the water content from the samples. The samples were preserved one night in 
96% alcohol and after a passage in absolute alcohol were submitted to Critical 
Point Drying and metallised with gold. The preparations obtained were observed 
with a scanning electron microscope (model: JMS Jeol 6490) in use at the CUGAS 
Interdepartmental Service Centre of the University of Padua.
Gene expression by Real-Time PCR
RNA extraction and quantification
The  RNA extraction  of  the  samples  was  carried  out  by  using  a  monophasic 
solution  based  on  phenol  and  guanidine  isothiocyanate,  TRIzol® Reagent 
(Invitrogen). 
The homogenization of the samples with such reagent causes the lysis of the cell 
membranes  guaranteeing  the  integrity  of  RNA inhibiting  the  activity  of  RNase 
enzymes.
The constructs  were transferred to  microtubes with 1 ml TRIzol® Reagent  and 
incubated  for  5  minutes  at  30°C  to  allow  for  their  complete  dissociation. 
Afterwards, 200 l chloroform were added to the samples and these were stirred 
for 30 seconds before incubation at room temperature for 2 further minutes. From 
the following centrifugation at 14000 rpm for 15 minutes at 4°C three phases were 
obtained: an upper, aqueous, limpid phase containing the RNA, a central, white 
interphase containing the DNA and a lower, pink phase containing proteins, phenol 
and chloroform. 
The aqueous phase was transferred into a new microtube and 500 l isopropanol 
were added to precipitate the RNA. After incubating the samples for 10 minutes at  
room temperature, these were centrifuged at 14000 rpm for 10 minutes at 4° C.
The pellet deriving from centrifugation, made up of the RNA, was washed with 1 
ml cold 75% ethanol, stirred and centrifuged at 14000 rpm for 5 minutes at 4° C.
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Afterwards,  the  RNA was  dried  at  room temperature  for  ten  minutes  and  re-
suspended in DNase RNase-free water.
RNA  quantification  was  carried  out  with  the  NanoDrop  spectrophotometer 
(NanoDrop™  1000,  Thermo  Scientific),  which,  besides  estimating  the 
concentration  of  the  samples,  determines  their  purity  from  contaminants.  The 
instrument provides the absorbance ratios 260/280 and 260/230, whose values 
must be respectively included in the ranges of 1.8-2 and 2-2.2 in order to consider 
the RNA samples pure from contaminants. Low values of such ratios indicate the 
presence of proteins, phenol and other organic contaminants that absorb around 
280 and 230 nm.
Synthesis of complementary DNA
Complementary DNA (cDNA) was synthesized following the Invitrogen protocol: 
First-Strand cDNA synthesis using M-MLV RT. Such protocol provides the use of 
the M-MLV RT (Moloney Murine Leukemia Virus Reverse Transcriptase) enzyme 
that,  using  the RNA strand as  a template,  synthesizes a complementary DNA 
strand.
For each sample, 500 ng RNA were retrotranscribed in a reaction volume equal to 
20  l.  In  nuclease-free microtubes were mixed:  1  μl  Oligo (dT)12-18 [500 μg/ml] 
(Invitrogen); 500 ng total RNA; 1 μl dNTP Mix [10 mM] (Invitrogen) and nuclease-
free distilled water up to the volume of 12 μl. The mixtures were heated to 65°C for 
5 minutes and then placed into ice for some minutes.
After  a  short  centrifugation  step  to  collect  the  content  on  the  bottom  of  the 
microtube, we added: 4 μl First-Strand Buffer 5X (Invitrogen); 2 μl DTT [0.1 M] 
(Invitrogen) and 1 μl  RNaseOUT Recombinant  Ribonuclease Inhibitor  [40 U/μl] 
(Invitrogen). The reaction mixtures, after being stirred gently, were incubated at 
37° C for 2 minutes. Afterwards, by pipetting gently, 1 μl M-MLV RT enzyme [200 
U/μl] (Invitrogen) was added to each sample. After incubating the samples at 37°C 
for 50 minutes, the reaction was inactivated by heating the samples to 70°C for 15 
minutes.
The so obtained cDNA was preserved at -20°C until its use as a template for PCR 
amplification.
Real-Time PCR
Real-Time PCR is an advanced version of polymerase chain reaction (PCR) that 
allows, through the use of dyes or fluorescent probes, to quantify in real time DNA 
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amplification by correlating  fluorescence intensity  with the concentration of  the 
PCR products. Each Real-Time PCR reaction is characterized by an accumulation 
of fluorescent signal that is defined by the Ct (cycle threshold), that is to say, by  
the number of cycles required to obtain a signal intensity higher than the ground 
noise of the system. To high amounts of initial DNA corresponds a fast increase in 
the fluorescent signal and, therefore, a low Ct value.
The fluorescent signal was generated by adding to the reaction mixture the SYBR 
Green I  fluorescent  dye.  It  is  an asymmetric  cyanine intercalating  the  double-
strand DNA. When the SYBR Green I molecules are free in solution they show no 
relevant fluorescence; on the contrary, when they bind to the double-helix DNA (in 
correspondence of the minor groove), they undergo a conformational change and 
considerably increase the amount of fluorescence emitted.
For each sample, 2.5 l cDNA were amplified in a reaction volume equal to 25 l. 
In nuclease-free 200-l  microtubes were mixed: 12.5 μl  FastStart  SYBR Green 
Master [2X] (Roche); 0.75 μl Forward primer [10 M]; 0.75 μl Reverse primer [10 
M];  8.5  l  Dnase-Rnase  free  water  (GIBCO).  After  gently  mixing  and  shortly 
centrifuging each mixture, 2.5μl cDNA were added. 
The  Real-Time  PCR  reactions  were  carried  out  in  a  Rotor-Gene  RG-3000A 
thermal  cycler  (Corbett  Research,  Australia),  following  the  amplification 
programme shown in Table 4.
Table 4: Amplification programme of the Real-Time PCR.
Cycles Passage Temperature Time
1 Initial denaturation of cDNA 95 °C 10 minutes
40
Denaturation 95 °C 10 seconds
Primer pairing 60 °C 30 seconds
Extension 72 °C 30 seconds
1 Final extension 72 °C 10 minutes
The cDNA samples were analysed in triple copy using the Primer pairs shown in 
Table 5.
The  genic  expression  analysis  was  determined  by  normalizing  the  amount  of 
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transcript of the gene of interest with that of the gene of reference (GAPDH) in the 
same sample. Normalization was carried out by applying the following formula:
2Ct
wherein 2 represents amplification efficiency equal to 100%,
Ct = Ct gene of reference - Ct gene of interest
Finally, the genic profiles were presented as the ratio (R) between the 2 Ct of the 
condition of reference (cell culture in the presence of differentiation factors) and 
the  normalized  2Ct of  the  control  condition  (cell  cultures  in  non-differentiation 
medium).
Table 5: Forward and Reverse Primers used in the Real-Time PCR analyses.
Gene Forward Primer (5’→3’) Reverse Primer (5’→3’)
CD31 TCCAGCCAACTTCACCATCC TGGGAGAGCATTTCACATACGA
I  Collagen 
1 TGAGCCAGCAGATCGAGA ACCAGTCTCCATGTTGCAGA
CNPase AGATGCGGTGGCTAAAGGTC TCTTAGGCAGCTCTTTGGGA
GAPDH TCAACAGCGACACCCAC GGGTCTCTCTCTTCCTCTTGTG
GFAP AGATCCGCACGCAGTATGAG AGGTCGCAGGTCAAGGA
Nestin TCAGAGGGAAGGAGATAGAGAGTC AGCCAGAAACCATATGTCAAGAGA
Osteocalcin GCAGCGAGGTAGTGAAGAGAC AGCAGAGCGACACCCTA
Osteonectin TGCATGTGTCTTAGTCTTAGTCACC GCTAACTTAGTGCTTACAGGAACCA
Osteopontin TGGAAAGCGAGGAGTTGAATGG GCTCATTGCTCTCATCATTGGC
PPAR CAGGAGATCACAGAGTATGCCAA TCCCTTGTCATGAAGCCTTGG
RUNX2 AGCCTTACCAAACAACACAACAG CCATATGTCCTCTCAGCTCAGC
S100 GACAAGTACAAGCTGAGCAAGAAG CCACAAGCACCACATACTCCTG
VEGFA GGACAGAAAGACAGATCACAGGTAC GCAGGTGAGAGTAAGCGAAGG
Vimentin CAGATGCGTGAAATGGAAGAGAAC GGTGGCAATCTCAATGTCAAGG
vWF ACGTATGGTCTGTGTGGGATC GACAAGACACTGCTCCTCCA
III 
≥ Tubulin CTCAGGGGCCTTTGGACATC CAGGCAGTCGCAGTTTTCAC
Cytogenetic analyses
Karyotype
The karyotype is a cytogenetic analysis that allows to visualize the chromosomes 
that  make up the  whole  genome of  an  eukaryotic  cell.  Therefore,  it  allows to 
distinguish the chromosomes on the basis of their number, shape and size and to 
appreciate any anomaly both in the number (trisomies and monosomies) and in 
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the structure (translocations, deletions and inversions).
In the cells the DNA appears like a non-analyzable disorganized mass, except for 
a  particular  phase  of  cell  division,  the  metaphase,  when  it  condenses  in  tidy 
structures: the chromosomes. The metaphase chromosomes can be marked with 
particular substances that bind to specific chromosome regions and that give them 
their typical band aspect. The marked chromosomes appear at the microscope like 
well-defined and easily identifiable structures; this allows to develop a cariogram, a 
tidy representation of the chromosomes paired on the basis of size, of the position 
of  the  centromere  and  of  the  banding.  Furthermore,  in  accordance  with 
international nomenclature, each pair is assigned a number from 1 to 22, and the 
sexual chromosomes are placed next to them.
The cells, previously inoculated in chamber slides (Lab Tek), were treated for 3 
hours with the alkaloid Colchicine 10 g/ml (Sigma Aldrich) to stop cell division at 
the  metaphase  stage.  Afterwards,  they  were  treated  for  15  minutes  with  a 
hypotonic  solution  (1%  solution  of  sodium  citrate  in  water)  to  break  the  cell 
membranes and disperse the chromosomes in a larger area. Afterwards the action 
of the hypotonic solution was blocked for 5 minutes with a fixative made up of 
ethanol and acetic acid in a 3:1 ratio. Then the fixative was applied twice more for  
15 minutes and the slides were left to dry in a humid environment.
The chromosomes were marked using the dye Quinacrine and were observed with 
the fluorescence microscope.
CGH array
The Comparative Genomic Hybridization (CGH) array is a technique that allows to 
identify any changes in the number of copies of the genes distributed all along the 
genome. It allows to quantify deletions or amplifications in the genome with an 
average resolution of 100 Kb, precisely defining the sizes and the start and end 
points of the regions involved in the unbalance.
It is possible to carry out a CGH array on any tissue from which it is possible to  
extract DNA, such as: peripheral blood, skin biopsy, solid tumours, marrow, chorial 
villi, amniotic fluid, fetal blood and cell cultures. For this reason, the CGH array 
finds application in several fields, such as: neuropsychiatry (in the diagnosis of 
mental  retardation,  autism,  epilepsy  and  malformation  of  the  cerebral  cortex), 
paediatrics  (to  confirm  congenital  anomalies,  developmental  alterations), 
obstetrics (in a suspected case of fetal chromosomal anomaly) and oncology (in 
the diagnosis of tumours of the hematopoietic lineage and solid tissues). 
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The CGH array was carried out by following the protocol  Agilent Oligonucleotide  
Array-Based  CGH for  Genomic  DNA Analysis (Agilent  Technologies),  which  is 
divided into the following phases:
- DNA Extraction: the target DNA was extracted from the samples using a ge-
nomic DNA extraction kit (Sigma).
- DNA Digestion: 500 ng target DNA and 500 ng control DNA were digested 
for 2 hours at 37°C with the enzymes RsaI and Alu I (Promega), which were 
subsequently inactivated for 20 minutes at 65°C.
- DNA marking and purification: The samples were marked for two hours us-
ing the marking Kit Quick Amp, two-colour (Agilent) by means of the “ran-
dom priming” technique with the cyanines Cy5-dUTP for the target DNA and 
Cy3-dUTP for the control DNA. Afterwards the marked products were puri-
fied with Amicon Ultra-0.5 30 K (Millipore).
- Hybridization on slides: The purified products were denatured and co-hy-
bridized on a 44K slide (Human Genome CGH Microarray, 4x44K, Agilent) 
loaded with probes (60bp oligomers) with an average resolution of about 
100 Kb. Hybridization was carried out in rotation at the controlled temperat-
ure of 65°C for 40 hours.
- Scanner reading and data analysis: At the end of incubation the slides were 
washed with particular washing buffers (Agilent) and read with the scanner 
G2505B  Agilent.  Data  were  processed  by  means  of  specific  software 
provided by Agilent (Feature Extraction and CGH-Analytics).
Use of CGH array for perimplantitis
To assess whether there is a relation to genetic predisposition and risk of peri-im-
plantitis, we have used this materials and methods.
We identified 20 patients with peri-implantitis and requested a blood test.
From a clinical point of view the diagnosis was performed by probing and radio-
graphic examination. 
All patients had infection with suppuration and marginal bone loss.
As a test, we have identified 5 patients with implants but without peri-implantitis. 
All patients had received treatment with implants at least 3 years with at least 2 im-
plants.
For all patients we required informed consent
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Array CGH has been conducted using the Agilent Human Genome CGH Microar-
ray Kit 44K and 180K (Agilent Technologies, Palo Alto, CA, USA) with a resolution 
of w75 kb.
Labeling and hybridization has been performed following the supplier’s protocols. 
We have used 4 mg of purified DNA obtained from 20 patient’s blood (with perim-
plantitis) and DNA obtained from  5 patients  without  perimplantitis as control . For 
all patients we required informed consent
It has been double-digested with RsaI and AluI for two hours at 37°C. 
After column purification, 1 mg of each digested sample has been labeled by ran-
dom priming (Invitrogen) for 2 hours using Cy5-dUTP for the patient’s DNA and 
Cy3- dUTP for the control DNA.
Labeled products has been column purified and prepared according to the Agilent 
protocol. After probe denaturation and pre-annealing with 50 mg of Cot-1 DNA, hy-
bridization has been performed at 65°C under rotation for 40 h. 
After two washing steps the array has been analyzed with the Agilent scanner and 
the Feature Extraction software (v8.0). 
Graphical overview has been obtained using the CGH analytics software (v3.1) 
(Agilent Technologies).
In Vivo
To test the ability of stem cells to promote bone regeneration and to test stem cells 
anti inflammatory capability we have have used those materials and methods with 
in vivo experiments. We have used both on small and large size animal.
In vivo rat model
The  in  vivo experiments were carried out  on four  immunocompromised female 
Wistar rats (Charles River) of 8 weeks. At the level of the cranial  bones some 
lesions were made,  which were then covered with the sample to be tested (a 
hydroxyapatite-based support previously cultured for one week with ADSCs in the 
presence  of  osteogenic  and  endothelial  factors)  or  with  the  control  (the 
hydroxyapatite-based support only).
All the operations were carried out upon general anaesthesia by means of the 
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intraperitoneal injection of ketamine hydrochloride (Ketaras, Yuhan Corporation, 
Korea, 40mg/kg) mixed with xylazine (Rompuns, Bayer Korea, Korea, 10 mg/kg). 
After  disinfecting  the  cutis  of  the  head  with  Betadine  10%  (Potadine,  Sam-Il  
Pharmacology, Korea) and injecting lidocaine (2% lidocaine containing. 1:100000 
epinephrine,  Lidocaine  HCL Injs.Yuhan  Corp.,  Korea)  into  the  skull  bone,  an 
incision was made along the sagittal suture, the periost was lifted and a lesion of 5 
mm of diameter was made using a trephine without perforating the dura.
Then the lesions were filled with the hydroxyapatite-based scaffold (control) only or 
with  the  scaffold  inoculated with  ADSCs.  After  the operation the animals were 
placed separately  in  cages thermostated at  22°C with  a  day/night  cycle  of  12 
hours and with food  ad libitum.  Three weeks after the operation the rats  were 
sacrificed by cervical dislocation.
All the animals were treated following the “Recommendations for the management 
of laboratory animals in biomedical research” issued by the Ethical Committee for 
Animal Experimentation of the University of Padua.
Goldner trichrome staining
The samples recovered from the  in vivo experiments were fixed for one night in 
3.7% formalin at 4°C, decalcified for 20 days with a solution based on formalin and 
formic acid, and included in paraffin. The inclusion in paraffin was carried out with 
the following passages:
- two 30-minute passages in 50% ethanol;
- three 30-minute passages in 70% ethanol;
- two 30-minute passages in 95% ethanol;
- two 30-minute passages in 100% ethanol;
- xylene until clearing;
- two one-hour passages in liquid paraffin in a heater at 60°C;
- inclusion.
The included samples were cut into slices having a thickness of 7 m, which were 
rehydrated  through  ascending  alcohols  and  submitted  to  Goldner  trichrome 
staining,  in  order  to  distinguish  the  mineralized bone from the  (unmineralized) 
osteoid.
Goldner trichrome staining (also known as Masson-Goldner) uses several dyes to 
stain the different structures. In particular, we used: ferric hematoxylin to make the 
nuclei brown-black, Light Green to make the collagen fibres green, acid fuchsin 
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and xylidine ponceau to  make the cytoplasm red,  and Orange G to  make the 
erythrocytes orange.
Staining was carried out as follows:
- ferric hematoxylin for 10 minutes;
- washed in distilled water;
- differentiated in spring water;
- acid fuchsin and xylidine ponceau for 5 minutes;
- washed in 1% acetic acid;
- differentiated in 1% phosphomolybdic acid for 5 minutes;
- washed in 1% acetic acid;
- Light Green for 2 minutes;
- washed in 1% acetic acid.
In vivo sheep model
Twenty  adult  female  sheep  were  used  for  the  experiment.  During  surgical 
procedures, the animals were premedicated with IM methadone (0.2-0.3 mg / kg) 
and xylazine (0.1 mg / kg), and then anesthesia was induced with propofol (3-5 
mg / kg IV). After the oro-tracheal intubation, general anesthesia was maintained 
with inhaled Isoflurane (1-1.6%, from 1.19 to 1.56 MAC) in oxygen/medical air.
The surgical field was prepared by shaving the skin to visualize main landmarks, 
namely, the angular vein of the eye and the transverse artery of the face. The 
sheep were prepped and draped in  a customary  manner  for  a  sterile  surgical 
procedure. The surgical site and the incision line were located and prepared with 
iodine.  Approximately  3.6  mL  of  local  anesthesia  (Polocaine  2%,  1:20  000 
levonordefrin;  Astra Pharmaceuticals,  Westborough, Mass) was administered in 
the surgical site. 
An oblique caudodorsal,  rostroventral,  extraoral  incision approximately  5  cm in 
length  was  made  over  the  most  ventral  aspect  of  the  maxillary  sinus. 
Subcutaneous  tissue  and  the  masseter  muscle  were  divided  to  expose  the 
maxillary periosteum, which was incised and elevated dorsally.  
The lateral wall of the sinus was approached with a surgical rotating tungsten bur 
to perform a rectangular surface antrostomy (Figure 10) under abundant irrigation 
with saline solution. 
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Figure  10:  rectangular  antrostomy  performed  with 
surgical bur to access the maxillary sinus
The antrum window was removed by fracturing along the osteotomy with a chisel 
instrument (Figure 11). 
Figure  11:  antrum window was removed. Schneiderian 
membrane was exposed
The sinus lining and floor were meticulously evaluated to remove any remaining 
soft tissue.
Maxillary sinus elevation was performed bilaterally in each sheep.
Sheep were divided into two groups of healing before sacrifice: 15 and 30 days. 
Each group consisted of 10 sheep of which six have received as a graft material in 
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one maxillary sinus hydroxyapatite based granular scaffolds biomaterial (Bio-oss® 
Bio-Oss;  Geistlich  Pharma  AG,  Wohlhusen,  Switzerland)  alone  whereas  the 
contralateral  side  received  granular  scaffolds  biomaterial  (Bio-oss® Bio-Oss; 
Geistlich Pharma AG, Wohlhusen, Switzerland) in presence of ADPSc. (Figure 12) 
Figure  12:  Schneiderian  membrane  was  elevated. 
Sinus  was  grafted  with  biomaterial  and  non  woven 
scaffold with ADPSc.
The  others  four  sheep  received  as  a  graft  material  in  one  maxillary  sinus 
hydroxyapatite based granular scaffolds biomaterial (Bio-oss® Bio-Oss; Geistlich 
Pharma AG,  Wohlhusen,  Switzerland)  alone plus  TNFα (10 mM) to  induce an 
inflammatory state whereas the contralateral side received hydroxyapatite based 
granular  scaffolds  biomaterial  (Bio-oss® Bio-Oss;  Geistlich  Pharma  AG, 
Wohlhusen, Switzerland) plus ADSc and TNFα (10 mM) to induce an inflammatory 
state.
An equal volume of graft material was used (3 cm3) within each sinus cavity. Deep 
and superficial fasciae of the masseter muscle were reapposed with 3–0 vicryl in a 
simple  continuous  pattern.  Subcutaneous  tissue  and  the  skin  were  closed 
separately in a similar manner with 3-0 vicryl. (Figure 13)
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Figure  13:  Subcutaneous  tissue  and  the  skin  were 
closed separately in a simple continuous pattern
The animals were treated i.v. with 15 mg/kg of ampicillin (Vetamplius®, Fatro) every 
12 h for 3 days and and tramadol 2 mg/kg. Surgical wounds were inspected daily. 
Groups of animals were euthanized at 15 and 30 days by applying an overdose of 
thiopental (Pentothal Sodium, Intervet) 10-15 mg/kg IV and embutramide (Tanax®).
The head were removed, and individual bone blocks containing the augmented 
sinus and the surrounding hard tissues were fixed.
Histological preparation
The  cellularized  scaffolds  were  fixed for  one  night  in  3.7%  formalin  at  4°C, 
decalcified for 20 days with a solution based on formalin and formic acid,  and 
included in paraffin.  The inclusion in paraffin was carried out with the following 
passages:
- two 30-minute passages in 50% ethanol;
- three 30-minute passages in 70% ethanol;
- two 30-minute passages in 95% ethanol;
- two 30-minute passages in 100% ethanol;
- xylene until clearing;
- two one-hour passages in liquid paraffin in a heater at 60°C;
- inclusion.
Serial  7-mm  sections  were  cut  perpendicular  to  the  osseous  defects  and 
surrounding bone (Reichert-Jung 2050, Nussloch, Germany). 
The  bone  sections  were  stained  with  haematoxylin  and  eosin  staining and 
Masson’s trichrome (MT) and observed under a light microscope.
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Semi-quantitative analysis of cells
In  order  to  analyze  the  cellular  response  to  treatments,  masked  microscopic 
examinations were performed on sections. Cells were identified by: haematoxylin 
and eosin staining, for: inflammatory cells, endothelial cells and fibroblasts;
by  Masson’s  trichrome (MT)  for  the  detection  bone  structure  (type  I  collagen, 
mature bone, woven bone). Briefly, two investigators analyzed in a masked fashion 
at  least  3  slides  for  each  experiment  by  light  microscopy  using  as  the  initial 
magnification. 
In vivo dog model
Six Labrador dogs were used for the experiment. During surgical procedures, the 
animals were pre-anaesthetized with atropina 0.04 mg/kg + medetomidina 0.04 
mg/kg + ketamina 5 mg/kg and sedated with isoflurano 1,5 a 3% CAM + O2 al 
95%.
All  mandibular  premolars and  the  first  molars  were  extracted bilaterally.  Three 
months after tooth extractions, a crestal incision was performed in the premolar-
molar  region  in  both  side of  the  mandible.  Full-thickness mucoperiosteal  flaps 
were  elevated,  and  six  experimental  sites  were  identified  in  the  edentulous 
alveolar ridges, each side of the mandible. The surgical preparation of the sites 
was performed according to the manual of the implant system (Sweden & Martina, 
Due Carrare, Padova, Italy). Twist drills were used to prepare each recipient site 
for  implants,  10  mm  long  and  3.3  mm  in  diameter  (Premium™,  Sweden  & 
Martina). 
Subsequently, especially designed step drills were used to widen the marginal 5 
mm of the implant bed to 5.4 mm. (Figure 14)
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Figure  14:  Surgical preparation of the sites. Especially 
designed step drills were used to widen the marginal 5 
mm of the implant bed to 5.4 mm
Implants were subsequently installed with their margin flush to the bone crest and 
healing caps were screwed on the implants.
Following installation, a marginal gap occurred around the implants. (Figure 15)
Figure  15:  Implants  were  installed  with  their  margin 
flush to the bone crest. A marginal gap occurred around 
the implants
The  marginal  defects  in  the  right  side  of  the  mandible  were  filled  with 
hydroxyapatite based granular scaffolds biomaterial (Bio-Oss®; spongious granule, 
particle size 0.25-1 mm; Geistlich Pharmaceutical, Wolhusen, Switzerland) mixed 
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with  a  concentrate  of  stem  cells  (ADSc).  The  defects  in  the  left  side  of  the 
mandible were filled with hydroxyapatite based granular scaffolds biomaterial (Bio-
Oss®;  spongious  granule,  particle  size  0.25-1  mm;  Geistlich  Pharmaceutical, 
Wolhusen, Switzerland) alone. (Figure 16)
  
Figure 16: A: marginal defects in the right side of the mandible were filled with 
biomaterial mixed with a concentrate of stem cells (ADSc). B: postoperative x-
ray showing implants with marginal defect. 
The flaps were sutured allowing a fully-submerge healing.
The sacrifice of the animals were planned after 1 month of healing. 
After  the  surgeries  the  animals  received antibiotic  for  8  days  (enrofloxacina  3 
ml/48 kg) and tramadol 2 mg/kg.
The animals were kept in kennels and on concrete runs at the university’s field 
laboratory with free access to water and fed with moistened balanced dogs’ chow.
Postoperatively,  the  wounds  were  inspected  daily  for  clinical  signs  of 
complications.  Check-ups  were  performed  on  regular  basis  throughout  the 
experiment.  The  animals  were  euthanatized  according  the  following  protocol: 
eparina 1000 UI + ketamine 10 mg/kg + xilacina 1mg/kg + succinilcolina 0.2 mg/kg 
and KCl 25 meq.
Histological preparation
The mandibles were removed, and individual bone blocks containing the implant 
and the surrounding soft and hard tissues were fixed in 4% formaldehyde solution. 
The  specimens  were  dehydrated  in  a  series  of  graded  ethanol  solutions,  and 
finally embedded in resin. 
The  blocks  were  cut  in  a  bucco-lingual  plane  following  the  long  axis  of  the 
A B
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implants, using a diamond band saw fitted in a precision slicing machine. A central  
section were harvested and then hand-polished and thinned to about 50 µm using 
a grinding machine. The histological slides were stained with Stevenel's blue with 
alizarin  red  and  examined  under  a  standard  light  microscope  for  histological 
analysis. (Figure 17)
Figure 17: histological slides were thinned to about 50 µm and 
stained with Stevenel's blue with alizarin red
With a light microscope for histological analysis (20x), all histological slides were 
observed  in  order  to  detect:  PMNs,  phagocytic  and  non  phagocytic  cells, 
fibroblasts,  endothelial  cells,  collagen  type  I  and  new  bone  formation. 
Neoangiogenesis  was  investigated  to  see  if  in  the  first  time  of  healing 
neoangiogenesis is accelerated by stem cells.
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Results
In Vitro
Culture of adult stem cells
Two different types of adult stem cells were isolated from their tissues of origin:
- Adipose derived Stem Cells (ADSCs) from the adipose tissue;
- Dental Pulp Stem Cells (DPSCs) from the dental pulp.
The  cell  suspensions  obtained  by  enzymatic  digestion  were  inoculated  on 
standard cell culture plates. After three days of culture, with the optical microscope 
one can see the presence of cells with fibroblastoid morphology adhering to the 
plastic (Figure 18).
a b
Figure  18: Optical  microscopiy  analysis  of  the 
primary culture of ADSCs (a) and DPSCs (b). 10X 
enlargements.
Before being inoculated on the biomaterial,  the adult stem cells were analyzed 
phenotypically by immunofluorescence (Figure 19) for the purpose of assessing 
the presence of the following markers on the cell surface:
- CD 73: also known as ecto-5'-nucleotidase. It is a 69 kDa protein anchored 
to the plasma membrane, where it catalyzes the conversion of extracellular 
nucleotides into nucleotides permeable to the cell membrane. It was found 
in hematocytes, in bone marrow cells and in thymic, renal and liver epitheli-
al cells.
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- CD 90: also known as Thy-1 (THYmocyte differentiation antigen 1) due to 
its first identification in thymocytes. It was also found on the surface of neur-
onal  cells,  endothelial  cells,  mesenchymal  stem cells  and hematopoietic 
stem cells.
- CD 105: also known as endoglin. It is a 180 kDa homodimeric transmem-
brane glycoprotein whose expression was found in endothelial cells and in 
embryonic stem cells, mesenchymal stem cells and bone marrow cells
CD73 CD90 CD105
a
b
Figure 19: Fluorescence microscopy analysis of the primary culture of ADSCs (a) 
and  DPSCs  (b).  Expression  of  CD73,  CD90  and  CD105  markers.  40X 
enlargements.
In vitro hard tissue reconstruction 
ADSC  and  DPSC  adult  stem  cells  were  used  in  combination  with  suitable 
biomaterials and differentiation factors in order to reconstruct hard tissue in vitro. 
In particular, the following tissue was reconstructed:
- vascularised bone tissue from ADSCs/DPSC inoculated on hydroxyapatite-
based scaffolds:
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Differentiation of ADSCs on a hydroxyapatite-based support
By means of enzymatic digestion, the adipose tissue-derived mesenchymal stem 
cells (ADSCs) were isolated and then amplified in complete DMEM medium for 
two weeks. Afterwards, the ADSCs were inoculated with a density of 106 cells/cm2 
on hydroxyapatite-based matrices, previously treated with fibronectin to favour cell 
adhesion. The matrices inoculated with the ADSCs were cultured in the presence 
of  differentiation  medium  made  up  of  osteogenic  and  endothelial  factors. 
Differentiation  was  prolonged  for  21  days  and  morphological  analyses, 
proliferation  tests,  gene  expression  and  molecular  cytogenetic  analyses  were 
carried out at intervals of 7 days.
A B
C D
Figure  20: Scanning electron microscopy (SEM) analysis  of  the construct 
based on hydroxyapatite (A) and inoculated with ADSCs after 7 (B), 14 (C) 
and 21 (D) days of culture in osteo-endothelial differentiation medium.
The morphological analysis of the constructs was carried out by SEM after 7, 14 
and  21  days  of  culture  in  osteo-endothelial  medium (Figure  20).  The  images 
acquired by SEM show that the ADSCs progressively colonized the biomaterial, 
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also proliferating inside the porous structure, until  constituting, after 21 days of 
culture, a continuous layer of cells (Figure 20 D).
The proliferation of the ADSCs inoculated on the hydroxyapatite-based scaffolds 
was also assessed by MTT assay (Figure 21 A) and by quantification of the cells 
adhering to the matrices (Figure 21 B) after 7, 14 and 21 days of culture in osteo-
endothelial  differentiation medium.  The quantification of  the adhering cells  was 
determined indirectly through a previously built calibration curve that correlates the 
amount of DNA extracted from the ADSCs to the number of cells subjected to 
extraction. The data collected show an increase in the proliferation time and in the 
number of ADSCs inoculated on the scaffolds.
A B
Figure  21: MTT assay  (A)  and  quantification  of  the  cells  adhering  (B)  to  the 
hydroxyapatite-based  supports  after  7,  14  and  21  days  of  culture  in  osteo-
endothelial differentiation medium.
The differentiation of the ADSCs inoculated on the hydroxyapatite-based matrices 
was assessed by genic expression analysis with Real-Time PCR (Figure 22).
To this purpose, three different differentiation conditions were tested:
- Three-dimensional cultures of ADSCs in the presence of osteogenic factors;
- Three-dimensional cultures of ADSCs in the presence of endothelial factors;
- Three-dimensional cultures of ADSCs in the presence of both factors.
Osteogenic differentiation was determined by assessing the expression of some 
bone matrix markers, such as Osteopontin, Osteonectin, Osteocalcin and Type I 
Collagen  [Ma  et  al.  2010].  On  the  other  hand,  endothelial  differentiation  was 
assessed by determining the expression of  the marker  CD 31 (also known as 
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Platelet Endothelial Cell Adhesion Molecule - PECAM-1), of the von Willebrand 
Factor (vW)  [Marino et al. 2012] and of the Vascular Endothelial Growth Factor 
(VEGF).  Furthermore,  the expression of transcriptional factors was determined: 
Runt-related  transcription  factor  2  (RUNX2),  essential  for  osteogenic 
differentiation, and Peroxisome Proliferator-Activated Receptors gamma (PPAR, 
necessary for the regulation of adipocyte differentiation [Kawai et al. 2009].
A
B
C
Figure  22: Genic  expression  analysis  by  Real-Time  PCR  of  ADSCs  in  the 
presence of osteogenic factors (A), endothelial  factors (B), and osteogenic and 
endothelial factors (C) after a treatment of 7 (black bars), 14 (white bars) and 21 
(grey bars) days.
In the presence of osteogenic factors only (Figure 22 A) there was an increase in 
the time of expression of the markers Osteopontin, Osteonectin, Osteocalcin and 
Type I Collagen. Over time, then, there was an increase in the expression of the 
osteogenic  transcriptional  factor  RUNX2  and  a  contemporary  reduction  in  the 
expression of the transcriptional factor PPAR, specific for adipocyte differentiation. 
In this differentiation condition there was no expression of the endothelial markers 
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CD 31, vW and VEGF.
The association of endothelial factors with osteogenic factors (Figure 22 C), on the 
other hand, showed over time a greater increase in the expression of osteogenic 
markers.  The same increase was also observed for  RUNX2 associated with a 
greater  reduction  in  the  expression  of  PPAR.  Furthermore,  the  presence  of 
endothelial  factors  determined the  expression  of  the  markers  CD 31,  vW and 
VEGF. For the latter, there was an increase in the expression over time like in the 
differentiation condition with endothelial factors only (Figure 22 B).
Genetic analysis of the construct
In order to ensure the genetic stability of the construct based on hydroxyapatite 
and differentiated ADSCs, Comparative Genomic Hybridization (CGH) arrays were 
performed to identify genomic deletions and amplifications.
The DNA extracted from the ADSCs inoculated on hydroxyapatite-based supports 
and treated with osteogenic and endothelial differentiation factors for 7, 14 and 21 
days was analysed by CGH array (Figure 23). This analysis showed the absence 
of  genomic  imbalances,  namely  amplifications  or  deletions  of  regions  of  the 
genome, confirming that long-term culture in the presence of differentiation factors 
cannot  induce DNA structural  alterations.  Figure  23 shows two  regions  as  an 
example of the whole genome of the analyzed samples. In particular, Figure 23 A 
shows  the  DNA region  related  to  the  MYC (myelocytomatosis  viral  oncogene 
homolog)  gene,  while  Figure  23 B  the  DNA  region  related  to  the  RB1 
(retinoblastoma 1) gene of the constructs after 7, 14 and 21 days. Both show no 
alterations, which are clearly evident in the same genomic regions of the positive 
control, represented by the DNA extracted from actinic keratosis cells (Figure 23 B 
and D).
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Figure  23:  CGH array analysis. Two genic regions of the hydroxyapatite-based 
scaffold inoculated with ADSCs in osteo-endothelial differentiation medium after 7, 
14 and 21 days (A, C) compared with the same regions of actinic keratosis (B, D).  
In (B) an amplification and in (D) a deletion.
Donor  age-related  biological  properties  of  human  dental  pulp  stem 
cells
Stemness of DPSCs
The isolation of DPSCs from human dental pulp and their  in vitro differentiation 
capacity  into  various  mesenchymal  tissues  were  first  established  by  using 
standard protocols. Under these conditions (using specific differentiation media), 
the classical adipogenic, osteogenic, and chondrogenic media were highly efficient 
in causing specific differentiation into the expected cell lineages, as confirmed by 
molecular hallmarks (Figure 24). 
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Figure  24:  Gene  expression  according  to  real-time  PCR  on  undifferentiated 
DPSCs  in  basal  culture  medium  (A)  and  in  media  that  induce  differentiation: 
chondrogenic (B), osteogenic (C) or adipogenic (D). One-way analysis of variance 
(ANOVA)  was  used  for  data  analyses.  The  Levene  ı́s  test  was  used  to 
demonstrate the equal  variances of  the variables.  Repeated-measures ANOVA 
with a post-hoc analysis using Bonferroni’s multiple comparison. T tests were used 
to determine significant  differences (p,0.05).  * p,0,05; *  *  p,0,01; *  *  *  p,0,001. 
Repeatability was calculated as the standard deviation of the difference between 
measurements.
Moreover, we analyzed the commitment to these lineages versus the expression 
of endothelial, neuronal and glial like features. First, to confirm that cells isolated 
from dental  pulp  with  our  protocols  were  dental  pulp  stem cells  (DPSCs),  we 
cultured the cells  in the presence of  basal  culture  medium for  undifferentiated 
DPSCs (Figure 24a), and we performed gene expression analyses to detect their 
phenotypes. After 2 days of culture in basal culture medium for undifferentiated 
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DPSCs, real-time PCR was performed. The genes selected for this screening were 
the following: Endothelial commitment: von Willebrand factor (vWF) and CD31. As 
reported in Figure 24a, no expression for these markers was detectable.
Bone commitment:  osteopontin,  osteonectin,  and osteocalcin.  No expression of 
these markers was detectable (Figure 24).
Neuronal commitment: S100, βIII tubulin, and nestin. Low expression of S100 was 
detectable, whereas no expression of other markers was found.
Glial commitment: GFAP and CNPase. Neither of these was detectable.
Adipogenic commitment: adiponectin, GLUT4, PPARγ. No expression was found.
Fibroblastic commitment: collagen type I was detected at 45% of the expression 
level of the control. 
Twin cultures were then performed for 21 days in different media: chondrogenic 
(Figure 24b),  osteogenic  (Figure  24c),  and adipogenic  (Figure  24d).  The gene 
expression patterns of the cultures confirmed the correct commitment. Indeed, in 
chondrogenic medium, only collagen type II was detectable, and no endothelial or 
neuronal  markers  were  present.  In  osteogenic  medium,  collagen  type  I, 
osteopontin, osteonectin, and osteocalcin were abundant, whereas no traces of 
collagen type II or adipogenic genes were observable. In adipogenic medium, no 
neuronal,  endothelial,  bone  or  cartilage  markers  were  detected.  PPARγ, 
adiponectin and GLUT4 (specific for adipogenesis) were observed (Figure 24d).
Proliferative activity
Population  doubling  time  (PDT)  is  used  to  evaluate  the  ability  of  the  cell  to 
duplicate in number and is therefore a direct marker of the proliferative ability of 
the  cell.  In  this  experiment,  we analyzed the  PDT of  DPSCs cultured in  non-
differentiative medium. PDT was evaluated at 3 different in vitro passages (p) of 
the cultures: 
 p2: early passage 
 p5: medium-term culture 
 p8: long-term culture 
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Figure 25: Population doubling time (PDT) of DPSCs cultured in the presence of 
basal culture medium for undifferentiated DPSCs. The graph shows in vitro pas-
sage (starting from p2 for young cells (black bar) to p8 (white bar)) and the age of 
the donor (from 16 to over 67). T tests were used to determine significant differ-
ences (p,0.05). * p,0,05; * * p,0,01; * * * p,0,001
As reported in Figure 25, we observed well-defined cell growth for each passage 
in  each  age  class.  For  the  aged  group  (up  to  67  years),  proliferative  ability 
decreased in time and during in vitro aging. This property was not evident for stem 
cells  derived  from young  donors  (up  to  25  years),  as  a  high  PDT value  was 
maintained in all cell passages. These data confirm the good proliferative ability of 
stem cells. After age 25, this ability decreased in proportion to the in vitro passage. 
Interestingly, up to age 56, a high level of proliferation was detectable at p2.
Qualitative analyses of lineage commitment
Qualitative and quantitative analyses of stemness were performed, starting from 
the data reported in the literature [Zhang et al. 2008; Volponi et al. 2010; Yan et al. 
2011;  Yang  et  al.  2010;  Huo  et  al.  2010;  Nakashima  et  al.  2009;  Sloan  and 
Waddington 2009]. The commitment ability of DPSCs was tested by culturing them 
in  the  presence  of  differentiation  media.   Markers  for  endothelium,  bone,  and 
nervous system were detected by immunostaining (Figure 26 and  Figure 27 for 
negative controls) and real-time PCR (Figure 28). 
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Figure  26:  Immunofluorescence  analyses  of  DPSCs  committed  to  several  cell 
lineages. (A) CD31 for endothelial cells (red cells). (B) Osteonectin for osteogenic 
commitment.  (C)  S100 (red cells,  for  neurogenic commitment),  (D)  nestin  (red 
fibers) and bIII tubulin (green), (E) GFAP (red staining), (F) CNPase (green) and 
nestin (red) (406) for glial-like commitment. (G) Negative control: DPSCs cultured 
in non-differentiative medium and stained with primary Ab against GFAP (no red-
positive cell  are detectable) and primary Ab against CNPase (no green-positive 
cells are detectable). Bar: 30 mm.
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Figure 27:  Immunofluorescence analyses of human fibroblasts (used as control). 
Bar: 30 mm.
Figure 28: Gene expression by real-time PCR on DPSCs in endothelial, neuronal 
or glial differentiation medium. One-way analysis of variance was used for data 
analyses. T tests were used to determine significant differences (p,0.05). * p,0,05; 
* * p,0,01; * * * p,0,001. Repeatability was calculated as the standard deviation of  
the difference between measurements.
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As control, DPSCs cultured in basal culture medium for undifferentiated DPSCs 
was. To test the specificity of the antibodies used for immunostaining, fibroblast 
cells were used as control. To analyze the results, we determined whether DPSCs 
always  expressed  the  correct  specific  markers  in  the  presence  of  a  given 
differentiation medium. If DPSCs expressed the expected markers, we referred to 
them as maintaining that differentiation phenotype, and if they did not, we referred 
to them as losing this ability.
Endothelial markers
Specific  markers  for  endothelial  commitment,  CD31  and  vWF,  were  selected. 
DPSCs cultured in the presence of endothelial differentiation medium expressed 
CD31,  as  indicated  by  the  well-defined  red  staining  (Figure  27 a).  Thus,  the 
DPSCs  correctly  committed  to  the  endothelial  phenotype.  Corroborating  the 
immunocytochemistry results, the gene expression (Figure 28) of CD31 and vWF 
also indicated endothelial differentiation.
Bone markers
Osteonectin, a bone-specific protein that binds selectively to both hydroxyapatite 
and collagen, was selected as a marker of commitment to bone cells. Osteonectin 
links  the  bone  mineral  and  collagen  phases,  perhaps  initiating  active 
mineralization in normal skeletal tissue. In the osteogenic medium, the red positive 
reaction (Figure 26 b) indicated the novel bone phenotype acquired by the cells. 
This  result  was  supported  by  the  expression  of  osteopontin,  osteocalcin  and 
collagen type I (Figure 28).
Neuronal markers 
To analyze neuronal  commitment  capacity,  we detected S100 (Figure 26 c),  a 
calcium-binding protein  normally  present  in cells  derived from the neural  crest 
(Schwann  cells  and  glial  cells),  in  mesenchymal-derived  cells  such  as 
chondrocytes and adipocytes, and in dendritic cells. In  Figure 26 c, it is evident 
that DPSCs expressed S100, as confirmed by the red fluorescent staining. Nestin, 
a type VI intermediate filament (IF) protein, is a protein marker for neural stem 
cells because it is mostly expressed in nerve cells. In our monolayer cell cultures, 
DPSCs in the presence of neuronal medium expressed nestin (Figure 26 d, red 
staining), further indicating neuronal commitment. The last protein tested for the 
neuronal  phenotype  was  βIII  tubulin,  a  protein  abundant  in  the  central  and 
peripheral nervous systems, where it is prominently expressed during fetal  and 
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post-natal  development.  All  of  the  DPSCs  cultured  in  neuronal  differentiation 
medium showed a positive expression of this neuronal protein (Figure 26 d, green 
staining; Figure 27, negative control). The gene expression detected with real-time 
PCR (Figure 28) confirmed the immunocytochemistry results.
Glial markers 
During gliogenesis, nestin is replaced by other IF proteins, such as glial fibrillary 
acidic protein (GFAP). In our cultures, indeed, no cells expressed GFAP if cultured 
in neuronal medium (data not shown), whereas in the presence of glial medium, a 
well-defined cytoskeletal structure positive for GFAP was evident (Figure 25 e, red 
staining).  Another  important  signal  related  to  glial  phenotypes  was  the  co-
expression of nestin and CNPase (Figure 25 f). CNPase (2',3'-cyclic nucleotide 3'-
phosphodiesterase) is expressed at high levels by oligodendrocytes in the central 
nervous system and by Schwann cells in the peripheral nervous system (Figure
25f,  green  staining).  Its  co-expression  with  nestin  (Figure  25f,  red  staining) 
confirmed the commitment of DPSCs to the correct phenotype. In  Figure 28, the 
gene expression levels of these proteins are shown. 
Quantitative analyses
We analyzed the percent of  positive cells for  each marker and compared their 
lineage  commitment  abilities.  These  analyses  were  performed  at  the  3  most 
significant in vitro passages of DPSCs (P2, P5, P8) for each age group (Figure 29) 
to test if the stemness of DPSCs is related to the  in vitro (passage) and  in vivo 
(age of donor) aging of the cells.
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Bone commitment
A marked in vitro commitment of DPSCs was detectable for each in vitro passage 
and for each age. Figure 29b shows that approximately 80% of DPSCs from both 
p2 and p5 acquired a bone phenotype when they were derived from patient of less 
of 55 years old. After this age, a strong commitment (approximately 70%) was still 
evident up to p8. 
Neuronal commitment
Nestin- (Figure 29c) and S100-positive cells (Figure 29d) were present at higher 
levels (100% of the cell population) during p2 (black bars) from donors up to 36 
years  old.  In  cells  from  donors  up  to  45  years  old,  Nestin  (Figure  29e)  was 
detectable in a smaller percentage of cell the population (80%), but its expression 
endured during the in vitro aging (from p2 to p8). Cells from senior donors showed 
a decrease in this marker over time in vitro.
GFAP (Figure 29f) and CNPase (Figure 29g) were present in approximately 70% 
of the cells in all p2 cultures for all ages. Starting from 45 years old, their presence 
dramatically decreased at p5 (gray bar) and at p8 (white bar).
3D cultures
Cells of the most representative groups, the 16-25 age group and the senior age 
group  (over  66)  at  p5,  were  seeded  onto  HA granules,  and  their  osteogenic 
potential was evaluated. The marker expression in monolayer conditions versus 
3D conditions were then compared. As shown in  Figure 30, the presence of HA 
considerably  improved  the  osteogenic  population:  osteopontin,  osteonectin, 
osteocalcin, collagen type I, collagen type III, cathepsin B (CTSB), cathepsin D 
CTSD,  distal-less  homeobox  1  (DLX1),  DLX5,  dental  sialoprotein  (DSPP), 
fibroblast growth factor 8 (FGF8),  transforming growth factor β1 (TGF-β1),  and 
RANK were more strongly expressed when cells where mixed with HA than in 
monolayer conditions from both donor age groups.
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Figure 30: Gene expression by real-time PCR on DPSCs derived from the younger 
donor group (16–25) and from the senior group (over 66) in monolayers and in 
nanostructured scaffolds. Markers selected were bone morphogenic protein (BMP) 
2, BMP-3, cathepsin B (CTSB), CTSD, collagen type I (Col1A1), collagen type III  
(Col3A1),  Distal-less homeobox (DLX) 1,  DLX5, fibroblast  growth factor  (FGF), 
transforming growth factor b1 (TGFb1), receptor activator of nuclear factor kappa-
B  (RANK),  osteopontin,  osteonectin,  and  osteocalcin.  The  results  for  each 
experiment  are  from quadruplicate  experiments.  Values  are  expressed  as  the 
mean 6  SD.  T tests  were  used to  determine significant  differences (p,0.05).  * 
p,0,05; * * p,0,01; * * * p,0,001.
Perimplantitis and CGH analysis: chromosomal aberration 
The  results  we  obtained  from  this  preliminary  study  of  20  patients  with  peri-
implantitis are the following
CGH array has been performed on DNA derived from blood sample collected from 
20 patients affected with perimplantitis. 
The result obtained, reported in fig.17 show for all the patient affected by perim-
plantitis, the presence of a duplication in omozygosis (red square) of a genome 
portion corresponding to the position at the chromosome 6, with starting point at 
43846044 pb position, and stop point position at 43862079 pb, for a total of 16 kb 
ca.
DNA derived from 5 patient with implants and not affected by perimplantitis has 
been also analised by CGH array and this duplication has not been detected (Fig-
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ure 31b ). A detailed analyses of this genomic portion revealed that this position 
correspond to the exon 8 of VEGF gene. 
Figure 31: A: presence of a duplication in omozygosis (red square) of a genome 
portion corresponding to the position at the chromosome 6. B: duplication has not 
been detected
In Vivo
In vivo rat implantation of the construct with ADSCs
For the purpose of testing the osteo-regenerative capacilities of the ADSCs,  in 
vivo experiments  were  carried  out  on  immunocompromised  Wistar  rats.  The 
experiments  of  implantation  on  the  animals  were  preceded  by  the  in  vitro 
preparation of the constructs: the ADSCs were inoculated on the hydroxyapatite-
based matrices with a density of 106 cells/cm2 and were later incubated for 7 days 
with  osteo-endothelial  medium.  These  constructs  were  then  implanted  in 
A                     B
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correspondence of lesions of the flat bones of the skull of immunocompromised 
rats.  The experiments were carried out by comparing the constructs previously 
prepared  in  vitro  (Figure  32b)  with  a  control  situation,  that  is  to  say,  the 
hydroxyapatite-based matrices with no cells (Figure 32a).
Figure  32: In vivo experiments. Implantation of the hydroxyapatite-based matrix 
with no cells (A) and of the hydroxyapatite-based matrix with ADSCs (B) in the flat 
bones of the rat skull. Goldner trichrome staining; 20x enlargements. In (C) genic 
expression analysis by Real-Time PCR of the hydroxyapatite-based matrix with no 
cells (white bars) and of the hydroxyapatite-based matrix with ADSCs (black bars).
Goldner trichrome staining performed on two different implants shows that both 
scaffolds  are  infiltrated  by  cells  with  the  deposition  of  extracellular  matrix,  in 
particular of Type I Collagen. What distinguishes the two implants is the presence 
of vessels in correspondence of the hydroxyapatite-based support inoculated with 
ADSCs.
Genic expression experiments were carried out on the implants by Real-Time PCR 
to confirm the histological analysis (Figure 32c). The data collected show that the 
presence of ADSCs in the construct guarantees the presence of a population of 
cells  from  the  osteogenic  phenotype  characterized  by  the  expression  of  the 
A B
C
92
markers Osteopontin, Osteonectin, Osteocalcin, Type I Collagen and RUNX2 and 
of a population of endothelial cells that express the markers CD 32, vW and VEGF.
In vivo rat implantation of the construct with DPSCs
The bone regeneration activity of the DPSCs was assessed in vivo using a rat 
calvarial defect model (Figure 33a; c).
Figure 33: Critical size defect (A, C) before 
the  treatment  with  DPSCs.  Defect  after 
treatment  with  DPSCs  from  the  younger 
group (B) and older group (D).
We considered 2  different  groups to  ascertain the influence of  undifferentiated 
DPSCs on new bone formation: DPSCs from the 16-25-year donor group (Figure
33b) and from the over-66 group at p5 (Figure 33d).  As controls,  HA granules 
without cells were used.
Concerning  the  cell  populations  filling  the  implants,  it  was  evident  that  no 
inflammatory reaction around or inside the implant containing stem cells (Figure
34) from either donor age group occurred (Figure 34a from the younger donor 
group; Figure 34b from the senior donor group).
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Figure  34:  In  vivo  engraftment  of  HA nanostructured  scaffolds  (van  Gieson 
staining, 206). (A) DPSCs from the younger group (16–25). (B) DPSCs from the 
senior group (.66). *, HA granules; black arrows, extracellular matrix. (C) Real-time 
PCR. Time course of osteogenic (osteopontin, osteonectin, osteocalcin, collagen 
type I, Runx2) and vasculogenic (CD31, vWF, VEGF) mRNA expression analyzed 
by  semi-quantitative  real-time  PCR  of  HA  nanostructured  scaffolds  in  vivo 
embedded with DPSCs after 21 days. The results for each experiment are from 
quadruplicate experiments. Values are expressed as the mean 6 SD. T tests were 
used to determine significant differences (p,0.05). * p,0,05; * * p,0,01; * * * p,0,001.
In both implants enriched with stem cells, the HA nanostructured granules (Figure
34c *) were fully embedded with osteoblast-like cells capable of producing a good 
extracellular matrix consisting mainly of collagen type I, as revealed by van Gieson 
staining (Figure 34c, black arrows). A more detailed analysis of the cell population 
was performed using real-time PCR for osteogenic markers. As shown in  Figure
33c,  the presence of HA considerably improved the osteogenic population: the 
markers for osteopontin, osteonectin, osteocalcin, collagen type I, RUNX, VEGF, 
CD31, vWF, and vascular endothelial growth factor (VEGF) were more strongly 
expressed when cells where mixed with HA than in monolayer conditions from 
both donor age groups.
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Sheep cellular response to scaffolds
Cellular events involved in bone regeneration are summarised in Table 6.
In normal regenerated tissue, the sites treated with HA and with HA with stem cells 
show at  15 days no infiltration  of  inflammatory  cells  population.  There are no 
polymorphic  nuclear  cells  (i.e.  granulocytes),  phagocytic  cells  (include 
macrophages and monocyte-derived giant cells) and non-phagocytic cells, plasma 
cells and mast cells. It should be noted that absolute numbers of PMNs and non-
phagocytic cells are lower than for phagocytic cells. Even if the sites without stem 
cells show a presence of fibroblasts, endothelial cells and type I collagen, sites 
treated with stem cells exhibit a greater number of these cells.
At day 30 with HA scaffolds alone a moderate presence of fibroblast, endothelial 
cells and collagen fibers is observable, while higher presence of all cells types and 
of  a  extracellular  matrix  well  structured is  revealed in  presence of  stem cells. 
(Table 6)
Table 6: Cells were scored from not present (-) to abundantly present (+++)
a PMNs = polymorphic nuclear cells, i.e. granulocytes
b Phagocytic cells include macrophages and monocyte-derived giant cells
c Non-phagocytic cells include lymphocytes, plasma cells and mast cells
At day 15, the presence of an inflammatory state  created using TNFα (10 mM), 
without  stem cells,  showed high  infiltration  of  granulocytes  and  macrophages. 
Scarce fibroblast,  endtothelial  cells and collagen fibers were observable in any 
site.  Treatment  with  stem cells  in  presence of  inflammed tissue showed a big 
Days after implantation PMNs
a
Phagocyt
ic cellsb
Non-
phagocyti
c
cells
Fibroblast
s
Endotheli
al
cells
Collag
en
type I
15  days  without  stem 
cells
- - - + + +
30  days  without  stem 
cells
- - - ++ ++ ++
15 days with stem cells - - - ++ ++ ++
30 days with stem cells - - - +++ +++ +++
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presence of inflammatory cells such as granulocytes and macrophages, scarce 
presence of fibroblast, and moderate quantity of endothelial cells and collagene 
type I fibers.
At day 30 the sites without stem cells showed a moderate amount of polymorphic 
nuclear  cells  (granulocytes),  phagocytic  cells  (macrophages)  and  some  non-
phagocytic  cells.  There is also a moderate presence of  fibroblasts,  endothelial 
cells and collagen type I cells. 
At  day  30  the  cellular  response  at  the  treatment  with  stem  cells  included  a 
significative  amount  of  endothelial  cells,  collagen  type  I  cells  and  fibroblasts.  
Polymorphic nuclear cells, phagocytic cells and non-phagocytic cells were scarce. 
Collagen fibers were present overall in stem cells-treated tissue. (Table 7)
Table 7: Cells were scored from not present (-) to abundantly present (+++)
HA scaffold treated with TNFα (10 mM)
Days  after 
implantation
PMNsa Phagocytic 
cellsb
Non-
phagocytic
cells
Fibroblasts Endothelial
cells
Collagen
type I
15  days 
without 
stem cells
+++ +++ ++ + + +
30  days 
without 
stem cells
++ ++ + ++ ++ ++
15  days 
with  stem 
cells
+++ +++ ++ + ++ ++
30  days 
with  stem 
cells
+ + + +++ +++ +++
In the site enriched with stem cells the HA granules were fully embedded with 
fibroblast-like  cells.  These cells  are  capable  of  producing  a  good  extracellular 
matrix consisting mainly of collagen type I, as revealed by Alzan Mallory staining in 
blue (black arrows). Also significantly vessel (yellow arrows) could be found inside 
the scaffolds. (Figure 35, Figure 36) The presence of extracellular matrix and neo 
angiogenesis is crucial in the process of healing.
96
Figure 35: 15 days of healing. Site with HA scaffold treated 
with  TNFα and stem cells.  Upper images are stained with 
EE, lower with Alzan Mallory. Yellow arrows indicate vessels, 
black ones fibroblasts. In EE staining, dark dots represents 
inflammatory cells.
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Figure  36: 30 days of healing. Site with HA scaffold treated 
with TNFα and stem cells. Upper images are stained with EE, 
lower with  Alzan Mallory. Black arrows indicate extracellular 
matrix.
Dogs cellular response to scaffolds
Cellular events involved in bone regeneration have been analyzed with Stevenel’s 
blue and alizarin  red.  These solutions stein  in  blue collagen fibers  and in  red 
mineralized tissues. (Figure 37)
Figure 37: Specimen 30 days after dental implant insertion. This preparation was 
obtained with Stevenel’s  blue and alizarin  red staining.  Note  the marginal  gap 
occurred around the implant filled with HA scaffold.
Histological specimen represented in (Figure 38 Figure 39) is a sample of healing 
30 days after fixture insertion. The site was regenerated with HA scaffold with stem 
cells. It can be noticed in black a portion of fixture, in pink the HA scaffold, in red 
the mineralized tissues and in blue collagen fibers.
In the site enriched with stem cells the HA granules were fully embedded with 
fibroblast-like  cells  capable of  producing  a  good extracellular  matrix  consisting 
mainly  of  collagen  type  I,  and  properly  mineralized  tissue.  No  inflammatory 
infiltrates are presents in the tissue. Significantly vessel (yellow arrows) could be 
found inside the scaffolds. Dental implant is well integrated with a good contact 
between new bone and implant surface. Where a large bone-to-implant contact 
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(BIC) is present, implant show a good stability and is considered osteointegrated.
Figure  38:  30  days  of  healing.  Stevenel’s  blue  and  alizarin  red 
staining.  The  site  was  regenerated  with  HA scaffold  with  stem 
cells. Pink staining indicate the HA scaffold, red the mineralized 
tissues and in blue collagen fibers. Yellow arrows indicate vessels. 
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Figure  39:  30 days of  healing.  Stevenel’s  blue and alizarin  red 
staining.  The  site  was  regenerated  with  HA scaffold  with  stem 
cells. Pink staining indicate the HA scaffold, red the mineralized 
tissues and in blue collagen fibers. Yellow arrows indicate vessels. 
Note the new bone formation.
Figure 39 shows a higher magnification (40x) the deposition of new bone matrix. 
There are numerous vessels that indicate a process of neo-angiogenesis and the 
scaffold of  HA stained in pink closer with osteoblasts stained in blue.  The red 
portion represent the new bone that is placed by osteoblasts directly in contact 
with the surface of the HA scaffolds.
At  day  30  after  surgery  both  sites  with  or  without  stem  cells  do  not  show 
polymorphic  nuclear  cells  (i.e.  granulocytes),  phagocytic  cells  (include 
macrophages and monocyte-derived giant cells) and non-phagocytic cells, plasma 
cells and mast cells. It should be noted that absolute numbers of PMNs and non-
phagocytic cells are lower than for phagocytic cells. 
Site without stem cells show a scarce amount of fibroblasts, endothelial cells and 
collagen type I cells. Also the new bone formation is scarce. In site treated with HA 
scaffold with stem cells there is larger amount of endothelial cells, collagen type I 
cells and the new bone formation is more evident. (Table 8)
Table 8: Cells were scored from not present (-) to abundantly present (+++)
Days after 
implantation
PMNsa Phagocytic 
cellsb
Non-phagocytic
cellsc
Fibroblasts Endothelial
cells
Collagen
type I
New 
bone
30 days without 
stem cells
- - - + + + +
30 days with stem 
cells
- - - + ++ ++ ++
a PMNs = polymorphic nuclear cells, i.e. granulocytes
b Phagocytic cells include macrophages and monocyte-derived giant cells
c Non-phagocytic cells include lymphocytes, plasma cells and mast cells
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Discussion
Injuries caused by trauma, edentulism condition, tumor or cyst resection, infectious 
diseases,  extreme  atrophy  after  tooth  extractions  may  result  into  serious 
functional, aesthetical and psychological sequelae [Cohen 1995; Hunt and Hobar 
2003].
In such situations, absence of hard and soft tissues can be disfiguring and often 
compromise basic functions such as : mastication, speech and also psychological 
conditions [Davis and Telischi 1994; Kadota et al. 2008; Curtis et al. 1997; Urken 
et  al.  1991].  The  progression  of  certain  oral  conditions  may  also  result  in 
craniofacial defects of difficult resolution. (Figure 40)
Periodontitis is a chronic inflammatory disease of bacterial etiology, characterized 
by the loss of support around teeth, including alveolar bone resorption and soft 
tissue alterations  [Genco 1992;  Kinane and Bartold  2007;  Feng and Weinberg 
2006]. 
Dental implant tooth replacements, one of the most popular therapies for total or 
partial edentulism, may be affected by a similar condition known as periimplantitis 
[Misch 2008]. Achieving predictable regeneration in the treatment of craniofacial 
defects  is  remarkably  challenging  in  most  clinical  scenarios  given  the  loss  of 
structural support and different embryologic origins of the affected tissues, among 
other factors.
Autogenous tissues have been widely used and are still considered as the gold 
standard to which all other biomaterials are compared [Dimitriou et al. 2011a]. 
Nevertheless,  even  the  most  advanced  reconstructive  techniques  using 
autologous  materials  are  often  insufficient  to  restore  extensive  or  complex 
maxillofacial defects [Susarla et al. 2011]. 
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Figure 40: Severe atrophy in the posterior mandibular. Lateral view (A, B); frontal 
view (C); occlusal view (D)
Figure  41:  sample  taking  of  bone  from 
retromolar zone
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Figure  42:  reconstructive  techniques  using 
autologous materials
Figure  43:  panoramic radiograph showing good bone 
regeneration and implant placement
  
Figure 44: Implant prosthetic rehabilitation in the posterior region
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Autografts contain all of the basic elements necessary to induce effective tissue 
regeneration, provided cells, extracellular matrix and cytokines [Pape et al. 2010; 
Khan et al. 2005]. However, the use of autogenous tissue involves the need of 
harvesting it from a donor site, with the consequent drawbacks in terms of costs, 
procedure time, patient discomfort and possible complications. (Figure 41,Figure
42,Figure 43, Figure 44)
Additionally, oftentimes the volume of harvested tissues is not sufficient to fill or 
cover a defect, given the limited availability of autogenous tissues [Dimitriou et al. 
2011b;  Zouhary  2010].  To  overcome these  limitations,  a  variety  of  exogenous 
substitute  materials,  including  allografts,  xenografts  and  alloplasts,  have  been 
introduced in clinical practice over the last three decades  [Bauer and Muschler 
2000; De Long et al. 2007]. These materials primarily act as scaffolds, supporting 
the  migration  of  cells  from the  periphery  of  the  grafted  area.  Substitutes  are 
indicated in the treatment of cases where the application of autografts alone may 
not  be  possible  [Finkemeier  2002].  Unfortunately,  when  comparing  these 
biomaterials  to  autografts  other  limitations  emerge.  The  presence  of  cellular 
populations, orchestrate the release of growth factors,  maintenance of a stable 
scaffold,  and  stimulate  angiogenesis  and  are  key  for  successful  tissue 
regeneration as they play a fundamental role on the healing process [Taba et al. 
2005]. Controlling the dynamics of these elements allows for a more predictable 
treatment of challenging craniofacial defect.
Novel  tissue  engineering  therapies  aimed  at  enabling  clinicians  to  achieve 
predictable regeneration have been recently developed.
The  idea  of  using  stem cells  for  therapeutic  purposes  has  become genuinely 
feasible, though it is clear from the scientific evidence accumulated to date that 
more research is needed first because there are still numerous problems to solve. 
In  particular,  although  embryonic  stem  cells  have  an  unlimited  potential  for 
differentiation, their use is restricted for various reasons. There are not only ethical 
issues to consider that hinder their transplantation, but also rejection phenomena 
and the risk of generating teratomas [Yu and Thomson 2008].
These are some of the reasons why adult mesenchymal stem cells (MSC) have 
been used in the field of tissue engineering. MSCs form a population of stromal 
cells  contained  in  the  bone  marrow  and  the  majority  of  postnatal  connective 
tissues.  They are capable of  differentiating not  only  into cells  of  mesenchymal 
derivation, but also into non-mesenchymal cell lines. In addition, cultured MSCs 
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have  a  marked  proliferative  capacity  as  well  as  retaining  their  potential  for 
multilinear differentiation, and this makes them interesting candidates for tissue 
regeneration purposes  [Augello and De Bari 2010].  Another favorable feature of 
MSCs lies in that they are readily available in postnatal tissues such as adipose 
tissue, and also – of more interest in dentistry – in dental pulp. 
Having the chance to harvest stem cells from teeth and then use them for bone 
regeneration  therapies  or  to  control  inflammatory  phenomena  such  as  peri-
implantitis  in the same patient is  undeniably  fascinating.  This would enable us 
biologically to ‘come full circle’, so that patients can use their own cells to treat  
themselves.
However  about  the  capacity  of  regeneration  of  bone  tissue,  it  has  an  innate 
capacity. 
It  is  generally  by  no  means  easy  for  it  to  heal  spontaneously  after  major 
resections, severe trauma, fractures or tumors and, when it comes to the world of 
dentistry, tooth extractions are always followed by some degree of physiological 
alveolar bone resorption.  Extracting a tooth entails the loss of the periodontal 
ligament and, with it, an associated loss of most of the blood flow to the bone 
tissue.  Studies in vitro (Pietrusson) and on animal models (Lindhe), and clinical 
studies too (Lindhe, Caneva) have all demonstrated shrinkage of the hard and soft 
tissues after a tooth has been extracted. The resulting condition of bone atrophy 
can also be exacerbated by the presence of movable prosthetics that come to 
bear directly on the alveolar mucosa, giving rise to severe bone resorption. Dental 
implants are a good therapeutic solution for edentulous patients because they can 
be used to support movable prostheses, and by transferring the masticatory load 
directly to the bone, they reduce bone resorption phenomena.  The amount of 
bone  available  is  not  always  sufficient  for  the  clinician  to  insert  an  implant, 
however, in which case it becomes necessary to resort to grafts of autologous or 
allogeneic  bone  tissue.   Autotransplants  and  allotransplants  have  produced 
promising results, but their use is limited for various reasons, including a limited 
availability, donor site morbidity, long recovery times, and the risk of transmitting 
disease [De Long et al. 2007] 
In  recent  years,  the  adoption  of  bone  substitutes  bio-engineered  with 
mesenchymal  stem  cells  (MSC)  has  developed  into  a  promising  alternative 
approach for the treatment of large bone defects without any of the side-effects 
associated with the more conventional therapies.  The use of cellularized bone 
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substitutes is also restricted, however,  because of their limited osteointegration, 
and this is due to the graft being poorly vascularized.
The cells in natural tissues are distributed so that they are never more than 200 
nm away from a capillary,  and this distance suffices to ensure the diffusion of 
oxygen, nutritional substances and waste.  Once implanted, the cells of tissues 
engineered in the laboratory should likewise come to be no further away from the 
nearest capillary in order to guarantee their survival [Lovett et al. 2009].  Generally 
speaking, when bone substitutes are transplanted into the host bone they become 
vascularized  as  a  consequence  of  the  inflammatory  response  needed  for  the 
lesion to heal.  The implanted cells’ state of hypoxia can also facilitate the graft’s 
vascularization  through  the  release  of  angiogenic  growth  factors.  This 
spontaneous vascularization is very limited, however, and the process is too slow 
to  reach  the  innermost  cells  of  the  implant.  The  vascularization  of  bone 
replacement  tissues  thus  remains  a  major  obstacle  to  overcome  before 
satisfactory clinical results can be obtained. 
In the light of these considerations, an in vitro model of vascularized bone tissue 
was  developed  starting  from  MSCs  harvested  from  adipose  tissue  (ADSCs). 
Adipose  tissue  is  an  interesting  source  of  MSCs  because  it  is  available  in 
abundance and readily accessible. In addition, it has been possible to obtain large 
numbers of cells in vitro in just a few culture steps, avoiding the risk of senescence 
and the onset of chromosomal anomalies. The multi-potency of ADSCs, thanks to 
their  mesenchymal  origin,  has  been  amply  demonstrated,  and  so  has  their 
capacity  for  osteogenic  differentiation  [Zuk  et  al.  2002].   ADSCs  are  also 
characterized  by  a  particular  plasticity  towards  the  endothelial  phenotype,  a 
feature  relating  to  the  origin  and  physiology  of  adipose  tissue.  In  fact,  the 
development  of  adipose  tissue correlates  closely  with  the  development  of  the 
capillary network essential to its maintenance: angiogenesis and adipogenesis are 
coordinated in time and space [Casteilla et al. 2011].  
Given the above considerations, the properties of ADSCs have been exploited in 
vitro  to  reconstruct  bone  tissue  with  vascular  elements  for  the  purpose  of  
facilitating cell survival after the graft has been implanted.  ADSCs were seeded on 
hydroxyapatite-based  matrices  and  grown  in  the  presence  of  osteogenic  and 
endothelial factors for 21 days. Morphological analyses, proliferation tests, gene 
expression analysis and molecular cytogenetic tests were completed every 7 days. 
Using SEM, the morphological analyses demonstrated a gradual proliferation of 
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the ADSCs also within the cavities in the biomaterial. After 21 days of culture in 
osteo-endothelial differentiating medium, the cells had formed a thin continuous 
layer over the surface of the biomaterial. The cells’ proliferation on the scaffold was 
also confirmed by means of the MTT-dye viability test and quantification of the 
cells adhering to the matrices. The osteogenic and endothelial differentiation of the 
ADSCs was established by means of gene expression analyses using real-time 
PCR.  Three differentiation methods were tested: 
(a) Three-dimensional culture of ADSCs in the presence of osteogenic factors; 
(b) Three-dimensional culture of ADSCs in the presence of endothelial factors; 
(c) Three-dimensional culture of ADSCs in the presence of both factors.
Already  after  a  week  of  culture  on  the  three-dimensional  support,  osteogenic 
differentiation had given rise to the expression of the bone matrix components 
osteopontin, osteonectin, and osteocalcin that are fundamental to the interaction 
between the extracellular matrix and the cells, and essential for the mineralization 
of the matrix.  The appropriate composition of the extracellular matrix was also 
confirmed by the expression of collagen type I, which is essential to the formation 
and  maturation  of  hydroxyapatite  crystals.  Osteogenic  differentiation  was  also 
ascertained by assessing the expression of the transcription factors RUNX2 and 
PPAR.  The  differentiation  of  MSCs  is  governed  by  the  expression  and/or 
activation of these transcription factors: RUNX2 determines their differentiation into 
osteoblasts, while PPAR prompts their differentiation into adipocytes.  PPAR also 
has  an  important  role  in  bone  metabolism  [Viccica  et  al.  2010].  It  facilitates 
adipogenesis at  the expense of  osteogenesis,  particularly  by inhibiting RUNX2 
function and reducing the number of osteoblasts in the bone marrow. Vice versa, 
an increase in RUNX2 expression inhibits adipogenesis and favors osteogenesis 
[Kawai  et  al.  2009].  In  the  presence  of  osteogenic  factors,  three-dimensional 
cultures of ADSCs reveal a gradual increase in RUNX2 expression coinciding with 
a  marked  reduction  in  the  expression  of  PPAR,  confirming  that  osteogenic 
differentiation occurs at the expense of adipogenic differentiation.  On the other 
hand, the osteogenic and endothelial  co-differentiation of the three-dimensional 
cultures of ADSCs prompted a faster increase in the expression of all the above-
mentioned  osteogenic  markers,  associated  with  a  prolonged  increase  in  the 
expression of the endothelial surface marker CD31, and of the soluble endothelial 
factors vW and VEGF. The three-dimensional co-differentiation thus led to the in 
vitro  reconstruction  of  a  cellularized  bone  substitute  comprising  an  osseous 
107
component  and  an  endothelial  component  essential  to  the  bone  substitute’s 
preservation  and  growth.  After  these  co-differentiated  constructs  had  been 
transplanted in vivo into immunocompromised rats, there was evidence of a proper 
capillary network having formed inside the material.
Scaffolds with  and  without  osteogenic  and endothelial  differentiated cells  were 
grafted on lesions prepared on flat cranial bones and, here again, morphological 
and molecular analyses conducted on the grafts 3 weeks after their implantation in 
vivo revealed the presence of  both  endothelial  osteogenic cell  lines  within  the 
grafts containing the stem cells. 
For  some  years  now,  any  transplantation  of  tissues  bio-engineered  in  the 
laboratory in humans has been subject to validation to ensure that they are safe in 
terms of the absence of any genetic alterations. Their safety in this sense could be 
ascertained by validating their  chromosomal  stability  by means of  a  karyotype 
analysis.  This  is  one  of  the  diagnostic  tests  most  commonly  used  to  identify 
chromosomal anomalies in the fields of oncology, gynecology and pediatrics. The 
method  is  based  on  the  culture  of  a  monolayer  of  cells  and  the  subsequent 
analysis under the microscope of the cells in metaphase after treating them with a 
mitotic  spindle blocker.  This  means that  karyotyping is not  applicable to  three-
dimensional cultures, and that is why the genetic stability of the osteo-endothelial  
constructs  was  analyzed  using  an  innovative  approach,  called  comparative 
genomic hybridization (CGH). This is a molecular cytogenetic technique based on 
the extraction of the cells’ DNA and the subsequent identification of any variations 
in  the  number  of  gene  pairs  distributed  throughout  the  genome.  This  method 
enables deletions and amplifications in the gene to be quantified with a greater 
resolution  than  karyotyping,  accurately  identifying  the  domains  and  the  points 
where  the  regions  involved  in  any  imbalance  start  and  end.   CGH  arrays 
demonstrated the genetic stability of the three-dimensional constructs, confirming 
that the long-term culture in the presence of differentiation factors is unable to 
induce structural DNA changes.
In conclusion, vascularized bone tissue was reconstructed in vitro by combining 
ADSCs  with  a  hydroxyapatite  scaffold.  Tests  demonstrated  that  the  ADSCs 
simultaneously differentiated into endothelial cells and osteogenic cells inside the 
same three-dimensional support, facilitating angiogenesis in the construct after its 
in vivo implantation. The development of new vessels inside the graft is a process 
essential  to  the  long-term  survival  of  the  implanted  cells  and  to  the 
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osteointegration of bio-engineered bone substitutes. CGH array analysis enabled 
us to  establish the genetic  safety  of  the construct  for  potential  implantation in 
humans.
In  the  light  of  the  findings  of  this  study  on  bone  reconstruction  in  vitro,  the 
feasibility of bone regeneration and/or post-extraction alveolar preservation with 
the  aid  of  stem  cells  and  biomaterials  would  pave  the  way  to  new  clinical 
strategies in the field of dentistry. From a social standpoint, this would be a great 
revolution for all the previously-mentioned biological reasons. More patients would 
be able to benefit from bone regeneration techniques, eliminating the problems 
relating to edentulism, and also those relating to bone harvesting from intra- or 
extra-oral sites and the associated morbidity. Last but not least, there would be 
advantages for both clinician and patient in terms of the timing and consequent 
costs of such treatments.
Regarding teeth istead, although they have complex structures that make them 
hard and strong,  they are vulnerable to  trauma and bacterial  infections.  When 
damaged teeth are still repairable, regenerating some parts of their structure may 
prevent or delay the loss of the whole tooth. This is important because tooth loss 
has more than just aesthetic consequences; it also affects the basal functions of 
the mouth and quality of life  [Huang 2009].  How tooth loss caused by trauma, 
caries or periodontal disease can be regenerated depends on the compartment 
involved because a tooth consists of tissues rich in cells, such as the periodontal 
ligament,  cement  and  pulp,  and  also  noncellular  tissues  like  the  enamel  and 
dentin. Of all the structural components of a tooth, only the enamel is incapable of 
regeneration;  all  the  other  tissues  have  a  more  or  less  marked  capacity  for 
regeneration, depending on a number of factors  [Inanç and Elçin 2011]. 
When the structure of a tooth is damaged, the pulp has an important role in its 
regeneration,  participating  in  a  process  called  the  reparative  dentinogenesis. 
When the dental pulp is exposed due to the enamel and the overlying dentin being 
lost,  coating  it  with  a  material  containing  calcium  oxide  enables  the  pulp  to 
generate new dentin.  The healthy pulp cells migrate to the site of  the damage 
where they proliferate thanks to the presence of growth factors released into the 
surrounding dentin matrix, and they form osteodentin over the necrotic layer. The 
cells  in  the  osteodentin  subsequently  differentiate  into  odontoblasts  that 
synthesize  the  reparative  dentin.  This  mineralized  tissue serves  two  important 
purposes: it keeps the pulp intact and it acts as a protective barrier  [Nakashima 
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2005]. 
Dentin regeneration is no longer possible, however, in cases of severe trauma, 
root  fractures,  or  destructive  caries,  when  it  becomes  necessary  to  either 
devitalize or extract the tooth. Since a vital dental pulp is fundamental to a tooth’s 
homeostasis and longevity, in cases where destructive caries have led to dental 
pulp necrosis, the ideal treatment would be a regenerative approach involving the 
removal of the diseased tissues and necrotic pulp and their replacement with new 
pulp tissue in order to revitalize the tooth. The goal of such regenerative therapy 
on the dental pulp is to reconstitute healthy pulp tissue for placing in the area 
adjacent to the dentin in order to prompt a process of reparative dentinogenesis. 
Depending  on  the  patient’s  clinical  conditions,  two  types  of  dental  pulp 
regeneration can be performed, i.e. a partial pulp regeneration in situ, or a total 
pulp replacement with de novo synthesized pulp [Sun et al. 2011].  
Sadly, dental pulp tissue regeneration and engineering is still difficult to achieve. 
The tissue of an engineered pulp needs to be fully functionalized: it  should be 
vascularized and innervated; it should have a cell density and extracellular matrix 
structurally similar to those of natural pulp; and it should be capable of generating 
new  odontoblasts  and  new  dentin.  The  first  step  in  dental  pulp  regeneration 
involves  the  isolation  and  amplification  of  cells  capable  of  differentiating  and 
producing  the  above-mentioned  structures.  The  use  of  dental  pulp  stem  cells 
(DPSCs) has been suggested for this purpose,  not  only because they are the 
physiological constituents of dental pulp, but also for their mesenchymal origin and 
capacity  to  differentiate  into  odontoblasts  [Gronthos  et  al.  2000] and  neurons 
[d'Aquino et al. 2009]. 
In  our  study,  as  illustrated  in  the  Materials  and  Methods  section,  and  in  the 
Results,  we succeeded in isolating stem cells from dental  pulp harvested from 
lower third molars.  By means of enzymatic digestion,  we isolated DPSCs from 
third molars extracted from donors of various ages to establish which age group 
enables large quantities of stem cells to be harvested in the shortest time possible.  
For this purpose, at various culture steps we calculated the population doubling 
time (PDT) for cells obtained from donors of various ages in the presence of non-
differentiating medium. 
The data obtained indicate that the DPSCs proliferate rapidly in the first culture 
steps irrespective of the donor’s age, while there was evidence of the PDT values 
dropping with increasing amplification steps. Only the DPSCs isolated from donors 
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who were between 16 and 25 years old followed a different trend, maintaining a 
constant proliferation rate irrespective of the number of culture steps. Given this 
feature, DPSCs deriving from individuals belonging to this age group were used 
for the reconstruction in vitro of  tooth-like tissue.  Before making the construct, 
preliminary immunofluorescence and gene expression tests were conducted on 
monolayers  of  cells  to  assess  the  DPSCs’  capacity  for  differentiation.  They 
underwent  glial,  neuronal  and  endothelial  differentiation,  demonstrating  the 
expression of the following markers: nestin, S100, CNPase and GFAP in the case 
of glial differentiation; nestin and III tubulin in the case of neuronal differentiation; 
and CD31 and vW in the case of endothelial differentiation. Having ascertained the 
DPSCs’  capacity  for  differentiation,  we  prepared  three-dimensional  constructs 
using a biomaterial obtained from the complete esterification of hyaluronic acid in 
order to mimic the fiber-rich structure of the extracellular matrix of dental pulp. 
These scaffolds were  steeped in  a  mixture of  glial  and neuronal  factors,  then 
DPSCs  were  seeded  on  them  in  the  presence  of  endothelial  differentiating 
medium.  After  14  days  of  differentiation,  the  constructs  were  analyzed  using 
immunofluorescence after  staining  with  hematoxylin  and eosin,  which  revealed 
cells  infiltrating  the  three-dimensional  scaffold,  the  deposition  of  extracellular 
matrix (and collagen type I in particular), and the expression of GFAP,  III tubulin 
and  vW,  which  are  markers  of  glial,  neuronal  and  endothelial  differentiation, 
respectively.
These results  thus enabled us to identify  a suitable source for obtaining large 
quantities of DPSCs within a short amount of time. Seeding these cells on a three-
dimensional scaffold consisting of hyaluronic acid in the form of the nonwoven 
fabric - similar to the extracellular matrix of dental pulp - could provide a model for  
dental pulp regeneration.  Moreover,  the DPSCs’ glial,  neuronal  and endothelial 
differentiation on these scaffolds makes the use of such substitutes promising for 
the regeneration of the nerve and vessel components of dental pulp.
These findings are not enough for any considerations on the efficacy of the model, 
however. Further analyses will need to be conducted to establish the utility of such 
a  construct  in  the  regeneration  of  dental  pulp.  Having said  that,  an  important 
aspect to emphasize of our study conducted on dental pulp is that we succeeded 
in demonstrating that stem cells can be isolated not only from the pulp of patients 
under thirty,  but also from that of adults between 60 and 70 years of age. We 
found the proliferative capacity of the latter’s DPSCs lower than in the case of 
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younger individuals, but it is important to know that even older adults can obtain 
stem cells from their own dental pulp for bone regeneration purposes.
Another issue to bear in mind when it comes to isolating stem cells from dental 
pulp is the type of tooth involved. The most suitable teeth for this purpose are 
those chosen for the present study, i.e. third molars (whether they have erupted or 
not), because the amount of pulp that can be extracted from an incisor or premolar 
tooth is not enough to enable the isolation of an adequate quantity of stem cells.
The  studies  carried  out on  animal  models have  shown the  potential of 
mesenchymal stem cells in the field of bone regeneration and of inflammation.  
Both in experiments on sheep and dogs, the presence of new blood vessels and 
extracellular matrix allows us to state how stem cells, with an appropriate scaffold, 
are able to promote bone regeneration faster. 
From a clinical point of view the advantages are manifold such as fewer surgeries, 
elimination of sample taking from the donor site, and a faster regeneration.
From a point of view of inflammation, mesenchymal stem cells (MSCs) are known 
to  migrate  to  tissue  injury  sites  to  participate  in  immune  modulation,  tissue 
remodeling and wound healing.
Indeed in dentistry,  tissue engineering could be consider  a  new frontier  in  the 
regeneration of missing oral  tissues/organs  [Koyano 2012; Kaigler and Mooney 
2001]. 
Our  results  are  comparable  with  other  reserch  where  stem cell-based  tissue 
engineering has already been applied to clinical trials with demonstrated efficacy 
in  orofacial  bone  tissue  regeneration  [Yamada et  al.  2006;  Ueda  et  al.  2008; 
Yamada et al. 2008; Kaigler et al. 2013].
Pieri et al.  [Pieri et al. 2010] demonstrated that the transplantation of autologous 
ASCs with an inorganic bovine bone scaffold (Bio-Oss1 )  enhanced new bone 
formation and implant osseointegration following vertical bone augmentation of the 
calvarial  bone of rabbits,  which suggests that  ASCs may be useful  for  vertical  
alveolar bone augmentation for implant treatment. [Wen et al. 2011]. 
Moreover,  Ishizaka  et  al.  [Ishizaka  et  al.  2012] demonstrated  that  ASC 
transplantation induced pulp regeneration in the root  canal  after pulpectomy in 
dogs, and Hung et al.  [Hung et al. 2011] demonstrated that ASCs implants were 
able to grow self assembled new teeth containing dentin, periodontal ligament and 
alveolar bone in adult rabbit extraction sockets with a high success rate. 
In addition to tissue repair and regeneration, immunomodulatory properties have 
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also recently been identified for MSCs in animals and humans that may be related 
to therapeutic effects such as angiogenesis, anti-inflammation and antiapoptosis 
[Nauta and Fibbe 2007]. Furthermore, recent reports suggest that MSCs have low 
inherent  immunogenicity  [Rasmusson  et  al.  2007].  Therefore,  the 
immunomodulatory properties of MSCs may make them more attractive than other 
types of stem cells for some applications in cell transplantation. 
In  a  recent  review  Ren  et  al. [Ren  et  al.  2012] underline  that  therapeutic 
mechanisms of MSCs include their homing efficiency to the tissue injury sites, their 
differentiation  potential,  their  capability  to  produce  a  large  amount  of  trophic 
factors,  and  their  immunomodulatory  effect.  Because  tissue  damage sites  are 
complicated milieus with distinct types of inflammatory cells and factors, available 
data  have  demonstrated  that  the  properties  of  MSCs  could  be  fundamentally 
influenced by the inflammatory elements.
The results obtained with the analysis of cgh for peri-implantitis are preliminary but 
are encouraging. We found a very interesting correspondence between  duplica-
tion-DNA and the presence of peri-implantitis. Unfortunately, we know little about 
the early diagnosis of peri-implantitis. However, this might be the right way to find 
those predisposed to the peri-implant disease. More studies are needed to confirm 
our results. 
In conclusion, research on all available stem cells in dentistry should be continued 
to  permit  their  manipulation for  the regeneration of  oral  tissues.  Based on the 
accumulated knowledge, the type of stem cell to be used for a given application 
will  be  decided  by  considering  a  balance  of  the  differentiation  capacity  with 
accessibility/availability, which may vary on a case-by-case basis.
Research  efforts  on  adult  stem  cells  and  pluripotent  stem  cells  should  be 
concomitantly performed with cross-communication to permit the development of 
new and effective strategies for regenerative dentistry.
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